Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 4th edition, 372 pages

+ the daily Top 10


  Malignant Melanoma

  Free Subscription


Articles published in Melanoma Res

Retrieve available abstracts of 363 articles:
HTML format



Single Articles


    October 2020
  1. KEUKELEIRE S, Schwarze J, Awada G, Everaert H, et al
    An atypical sarcoid-like reaction during anti-protein death 1 treatment in a patient with metastatic melanoma.
    Melanoma Res. 2020;30:524-527.
    PubMed     Abstract available


  2. SHIN J, Ho Lee D, Lee WJ, Park CS, et al
    Mycosis fungoides development after combined immune checkpoint blockade therapy in a patient with malignant melanoma: a case report.
    Melanoma Res. 2020;30:515-518.
    PubMed     Abstract available


  3. CAINI S, Gandini S, Botta F, Tagliabue E, et al
    MC1R variants and cutaneous melanoma risk according to histological type, body site, and Breslow thickness: a pooled analysis from the M-SKIP project.
    Melanoma Res. 2020;30:500-510.
    PubMed     Abstract available


  4. DIAMANTOPOULOS PT, Tsatsou K, Benopoulou O, Bonou M, et al
    Concomitant development of neurologic and cardiac immune-related adverse effects in patients treated with immune checkpoint inhibitors for melanoma.
    Melanoma Res. 2020;30:484-491.
    PubMed     Abstract available


  5. SENGUL SAMANCI N, Celik E, Bagcilar O, Erol BC, et al
    Loss of skeletal muscle area and fat-free mass during dabrafenib/trametinib and vemurafenib/cobimetinib treatments in patients with BRAF-mutant metastatic malignant melanoma.
    Melanoma Res. 2020;30:477-483.
    PubMed     Abstract available


  6. VELTER C, Marzouki-Zerouali A, Robert C
    Is it melanoma? Ask my dog!
    Melanoma Res. 2020;30:529-530.
    PubMed    


    August 2020
  7. MAZZINI C, Pieretti G, Vicini G, Nicolosi C, et al
    Clinical outcomes and secondary glaucoma after gamma-knife radiosurgery and Ruthenium-106 brachytherapy for uveal melanoma: a single institution experience.
    Melanoma Res. 2020 Aug 20. doi: 10.1097/CMR.0000000000000689.
    PubMed     Abstract available


  8. DIVINCENZO MJ, Latchana N, Abrams Z, Moufawad M, et al
    Tissue microRNA expression profiling in hepatic and pulmonary metastatic melanoma.
    Melanoma Res. 2020 Aug 13. doi: 10.1097/CMR.0000000000000692.
    PubMed     Abstract available


  9. WILSON MA, Zhong J, Johannet P, Lee Y, et al
    Preliminary analysis of distinct clinical and biologic features of bone metastases in melanoma.
    Melanoma Res. 2020 Aug 13. doi: 10.1097/CMR.0000000000000691.
    PubMed     Abstract available


  10. SAMARAN Q, Belakebi D, Theret S, Becquart O, et al
    Hemophagocytic lymphohistiocytosis in advanced melanoma treated with dabrafenib and trametinib combination: two cases.
    Melanoma Res. 2020 Aug 7. doi: 10.1097/CMR.0000000000000690.
    PubMed     Abstract available


  11. HOLTKAMP LHJ, Chakera AH, Fung S, Stretch JR, et al
    Staging 18F-FDG PET/CT influences the treatment plan in melanoma patients with satellite or in-transit metastases.
    Melanoma Res. 2020;30:358-363.
    PubMed     Abstract available


  12. CHAVANET A, Hill KR, Jimenez-Andrade Y, Choo MK, et al
    Intracellular signaling modules linking DNA damage to secretome changes in senescent melanoma cells.
    Melanoma Res. 2020;30:336-347.
    PubMed     Abstract available


    July 2020
  13. FUJIMURA T, Tanita K, Ohuchi K, Sato Y, et al
    Increased serum CCL26 level is a potential biomarker for the effectiveness of anti-PD1 antibodies in patients with advanced melanoma.
    Melanoma Res. 2020 Jul 8. doi: 10.1097/CMR.0000000000000685.
    PubMed     Abstract available


  14. ZIEGLER JS, Kroeze S, Hilbers ML, Imhof L, et al
    Toxicity of combined targeted therapy and concurrent radiotherapy in metastatic melanoma patients: a single-center retrospective analysis.
    Melanoma Res. 2020 Jul 8. doi: 10.1097/CMR.0000000000000682.
    PubMed     Abstract available


    June 2020
  15. TAS F, Erturk K
    Paradox in melanoma: more patients fewer publications.
    Melanoma Res. 2020 Jun 23. doi: 10.1097/CMR.0000000000000684.
    PubMed     Abstract available


  16. ZANELLA A, Doussot A, Puzenat E, Aubin F, et al
    MEK inhibitors combined with programmed cell death-1 blockade immunotherapy for metastatic uveal melanoma: is it warranted?
    Melanoma Res. 2020 Jun 23. doi: 10.1097/CMR.0000000000000677.
    PubMed     Abstract available


  17. HADFIELD MJ, Helsing R, Grant-Kels JM
    Desmoplastic melanoma: an updated clinical review and the emerging role of genetic markers and immunotherapies.
    Melanoma Res. 2020 Jun 23. doi: 10.1097/CMR.0000000000000679.
    PubMed     Abstract available


  18. LUCARINI G, Simonetti O, Lazzarini R, Giantomassi F, et al
    Vascular endothelial growth factor/semaphorin-3A ratio and SEMA3A expression in cutaneous malignant melanoma.
    Melanoma Res. 2020 Jun 8. doi: 10.1097/CMR.0000000000000674.
    PubMed     Abstract available


  19. FRANKE V, Smeets PMG, van der Wal JE, van Akkooi ACJ, et al
    Complete response to talimogene laherparepvec in a primary acral lentiginous melanoma.
    Melanoma Res. 2020 Jun 8. doi: 10.1097/CMR.0000000000000673.
    PubMed     Abstract available


  20. SOH BW, Kim YC, Choi JW
    Epidemiology of cutaneous melanoma and melanoma in situ: a 10-year nationwide retrospective cohort study in South Korea.
    Melanoma Res. 2020;30:297-302.
    PubMed     Abstract available


    May 2020
  21. VIDARSDOTTIR L, Fernandes RV, Zachariadis V, Das I, et al
    Silencing of CEBPB-AS1 modulates CEBPB expression and resensitizes BRAF-inhibitor resistant melanoma cells to vemurafenib.
    Melanoma Res. 2020 May 27. doi: 10.1097/CMR.0000000000000675.
    PubMed     Abstract available


  22. VERA AGUILERA J, Paludo J, McWilliams RR, Zhang H, et al
    Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients.
    Melanoma Res. 2020 May 11. doi: 10.1097/CMR.0000000000000669.
    PubMed     Abstract available


  23. JANELA-LAPERT R, Bouteiller J, Deschamps-Huvier A, Duval-Modeste AB, et al
    Anti-PD-1 induced collagenous colitis in metastatic melanoma: a rare severe adverse event.
    Melanoma Res. 2020 May 11. doi: 10.1097/CMR.0000000000000665.
    PubMed     Abstract available


  24. DALMASSO C, Pages C, Chaltiel L, Brun A, et al
    Survival estimation of melanoma patients with brain metastasis using the Melanoma-molGPA score: external validation from a French cohort.
    Melanoma Res. 2020 May 11. doi: 10.1097/CMR.0000000000000670.
    PubMed     Abstract available


  25. CONIC RRZ, Knackstedt R, Sussman TA, Rambhia S, et al
    Utilization and impact of immunotherapy in stage IV melanoma using the National Cancer Database.
    Melanoma Res. 2020 May 11. doi: 10.1097/CMR.0000000000000672.
    PubMed     Abstract available


    April 2020
  26. AUDREY-BAYAN C, Trager MH, Gartrell-Corrado RD, Rizk EM, et al
    Distinguishing melanophages from tumor in melanoma patients treated with talimogene laherparepvec.
    Melanoma Res. 2020 Apr 22. doi: 10.1097/CMR.0000000000000661.
    PubMed     Abstract available


  27. XIAO T, Chen W, Wang S, Huang S, et al
    Tacrolimus and ascomycin inhibit melanoma cell growth, migration and invasion via targeting nuclear factor of activated T-cell 3.
    Melanoma Res. 2020 Apr 13. doi: 10.1097/CMR.0000000000000663.
    PubMed     Abstract available


  28. DAVIS LE, Shalin SC, Tackett AJ
    Utility of histone H3K27me3 and H4K20me as diagnostic indicators of melanoma.
    Melanoma Res. 2020;30:159-165.
    PubMed     Abstract available


  29. FONDELLO C, Agnetti L, Glikin GC, Finocchiaro LME, et al
    Proliferation index and pseudoprogression as predictors of the therapeutic efficacy of suicide gene therapy for canine melanoma.
    Melanoma Res. 2020;30:126-135.
    PubMed     Abstract available


    March 2020
  30. CYBULSKA-STOPA B, Rogala P, Czarnecka AM, Galus L, et al
    BRAF and MEK inhibitors rechallenge as effective treatment for patients with metastatic melanoma.
    Melanoma Res. 2020 Mar 25. doi: 10.1097/CMR.0000000000000662.
    PubMed     Abstract available


    February 2020
  31. PADRNOS LJ, Houghton OM, Iacob CE, Kurli M, et al
    Genomic profiling proves metastasis of cutaneous melanoma to vitreal fluid.
    Melanoma Res. 2020 Feb 17. doi: 10.1097/CMR.0000000000000655.
    PubMed     Abstract available


  32. KOWALIK A, Jurkowska M, Mierzejewska E, Lugowska I, et al
    The prognostic role of BRAF and WNT pathways activation in kinase inhibitors-naive clinical stage III cutaneous melanoma.
    Melanoma Res. 2020 Feb 17. doi: 10.1097/CMR.0000000000000658.
    PubMed     Abstract available


  33. BUCHEIT AD, Hardy JT, Szender JB, Glitza Oliva IC, et al
    Conception and viable twin pregnancy in a patient with metastatic melanoma while treated with CTLA-4 and PD-1 checkpoint inhibition.
    Melanoma Res. 2020 Feb 17. doi: 10.1097/CMR.0000000000000657.
    PubMed     Abstract available


    January 2020
  34. WIND TT, Gacesa R, Vich Vila A, de Haan JJ, et al
    Gut microbial species and metabolic pathways associated with response to treatment with immune checkpoint inhibitors in metastatic melanoma.
    Melanoma Res. 2020 Jan 27. doi: 10.1097/CMR.0000000000000656.
    PubMed     Abstract available


    December 2019
  35. ATKINSON V, Sandhu S, Hospers G, Long GV, et al
    Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II).
    Melanoma Res. 2019 Dec 30. doi: 10.1097/CMR.0000000000000654.
    PubMed     Abstract available


  36. ROZEMAN EA, Prevoo W, Meier MAJ, Sikorska K, et al
    Phase Ib/II trial testing combined radiofrequency ablation and ipilimumab in uveal melanoma (SECIRA-UM).
    Melanoma Res. 2019 Dec 26. doi: 10.1097/CMR.0000000000000653.
    PubMed     Abstract available


  37. CERCHIO R JR, Marinaro C, Foo TK, Xia B, et al
    Nonhomologous end-joining repair is likely involved in the repair of double-stranded DNA breaks induced by riluzole in melanoma cells.
    Melanoma Res. 2019 Dec 17. doi: 10.1097/CMR.0000000000000652.
    PubMed     Abstract available


    November 2019
  38. JACOMASSO T, Ribas HT, Trombetta-Lima M, Silberspitz Konig M, et al
    The alternatively spliced RECK transcript variant 3 is a predictor of poor survival for melanoma patients being upregulated in aggressive cell lines and modulating MMP gene expression in vitro.
    Melanoma Res. 2019 Nov 18. doi: 10.1097/CMR.0000000000000650.
    PubMed     Abstract available


  39. HANNA DL, Law SJ, Merrick SA, Heptinstall L, et al
    The successful use of pembrolizumab in a renal transplant recipient with metastatic melanoma.
    Melanoma Res. 2019 Nov 18. doi: 10.1097/CMR.0000000000000651.
    PubMed     Abstract available


    October 2019
  40. HUYNH S, Lheure C, Franck N, Goldman-Levy G, et al
    Induced sarcoid-like reactions in patients with metastatic melanoma treated with dabrafenib and trametinib: a monocentric retrospective study.
    Melanoma Res. 2019 Oct 25. pii: 00008390-900000000-99122.
    PubMed     Abstract available


  41. MADU MF, Franke V, Van de Wiel BA, Klop WMC, et al
    External validation of the American Joint Committee on Cancer 8th edition melanoma staging system: who needs adjuvant treatment?
    Melanoma Res. 2019 Oct 22. doi: 10.1097/CMR.0000000000000643.
    PubMed     Abstract available


  42. DELGADO-HERNANDEZ R, Hernandez-Balmaseda I, Rodeiro-Guerra I, Cesar Rodriguez Gonzalez J, et al
    Anti-angiogenic effects of mangiferin and mechanism of action in metastatic melanoma.
    Melanoma Res. 2019 Oct 22. doi: 10.1097/CMR.0000000000000647.
    PubMed     Abstract available


  43. THUMMALAPALLI R, Melms JC, Mier J, Izar B, et al
    Rapid evolution of acute kidney injury after initial infusion of pembrolizumab in a melanoma patient concurrently treated with RAF/MEK inhibitors.
    Melanoma Res. 2019 Oct 17. doi: 10.1097/CMR.0000000000000646.
    PubMed     Abstract available


  44. THOMSEN H, Chattopadhyay S, Hoffmann P, Nothen MM, et al
    Genome-wide study on uveal melanoma patients finds association to DNA repair gene TDP1.
    Melanoma Res. 2019 Oct 11. doi: 10.1097/CMR.0000000000000641.
    PubMed     Abstract available


  45. JOHANSSON PA, Nathan V, Bourke LM, Palmer JM, et al
    Evaluation of the contribution of germline variants in BRCA1 and BRCA2 to uveal and cutaneous melanoma.
    Melanoma Res. 2019;29:483-490.
    PubMed     Abstract available


    September 2019
  46. LI C, Liu T, Tavtigian SV, Boucher K, et al
    Targeted germline sequencing of patients with three or more primary melanomas reveals high rate of pathogenic variants.
    Melanoma Res. 2019 Sep 24. doi: 10.1097/CMR.0000000000000645.
    PubMed     Abstract available


  47. KOSCHE C, Stout M, Sosman J, Lukas RV, et al
    Dermatomyositis in a patient undergoing nivolumab therapy for metastatic melanoma: a case report and review of the literature.
    Melanoma Res. 2019 Sep 24. doi: 10.1097/CMR.0000000000000642.
    PubMed     Abstract available


  48. CHRISTENSEN JN, Schmidt H, Steiniche T, Madsen M, et al
    Identification of robust reference genes for studies of gene expression in FFPE melanoma samples and melanoma cell lines.
    Melanoma Res. 2019 Sep 24. doi: 10.1097/CMR.0000000000000644.
    PubMed     Abstract available


  49. SALGADO C, Kwesi-Maliepaard EM, Jochemsen AG, Visser M, et al
    A novel germline variant in the DOT1L gene co-segregating in a Dutch family with a history of melanoma.
    Melanoma Res. 2019 Sep 12. doi: 10.1097/CMR.0000000000000640.
    PubMed     Abstract available


  50. SAXENA R, Wang Y, Mier JW
    CXCR4 inhibition modulates the tumor microenvironment and retards the growth of B16-OVA melanoma and Renca tumors.
    Melanoma Res. 2019 Sep 12. doi: 10.1097/CMR.0000000000000639.
    PubMed     Abstract available


    August 2019
  51. MORENO-ARRONES OM, Zegeer J, Gerbo M, Manrique-Silva E, et al
    Decreased vitamin D serum levels at melanoma diagnosis are associated with tumor ulceration and high tumor mitotic rate.
    Melanoma Res. 2019 Aug 28. doi: 10.1097/CMR.0000000000000638.
    PubMed     Abstract available


  52. PRIOR L, Toomey S, Greally M, Keane F, et al
    Genomic profiling of a dedifferentiated mucosal melanoma following exposure to immunotherapy.
    Melanoma Res. 2019 Aug 14. doi: 10.1097/CMR.0000000000000636.
    PubMed     Abstract available


  53. SORICH MJ, Rowland A, Hopkins AM
    Validation of dabrafenib-trametinib prognostic groups in patients treated with vemurafenib and cobimetinib for advanced BRAF-mutated melanoma.
    Melanoma Res. 2019 Aug 14. doi: 10.1097/CMR.0000000000000634.
    PubMed     Abstract available


  54. POSTOW MA, Chasalow SD, Kuk D, Panageas KS, et al
    Absolute lymphocyte count as a prognostic biomarker for overall survival in patients with advanced melanoma treated with ipilimumab.
    Melanoma Res. 2019 Aug 14. doi: 10.1097/CMR.0000000000000633.
    PubMed     Abstract available


  55. HUSSAIN RN, Heimann H, Damato B
    Neoadjuvant intravitreal ranibizumab treatment in high-risk ocular melanoma patients: a two-stage single-centre phase II single-arm study.
    Melanoma Res. 2019 Aug 14. doi: 10.1097/CMR.0000000000000635.
    PubMed    


  56. MAIEZZA S, Greliak A, Rached HA, Mortier L, et al
    Exacerbation of skin psoriasis when associating an MEK inhibitor with anti-PD1 immunotherapy for metastatic melanoma.
    Melanoma Res. 2019;29:447-448.
    PubMed    


  57. MARCE D, Cornillier H, Denis C, Jonville-Bera AP, et al
    Partial response of metastatic melanoma to BRAF-inhibitor-monotherapy in a pregnant patient with no fetal toxicity.
    Melanoma Res. 2019;29:446-447.
    PubMed    


  58. RAYNER JE, McMeniman EK, Duffy DL, De'Ambrosis B, et al
    IRF4 rs12203592*T/T genotype is associated with nodular melanoma.
    Melanoma Res. 2019;29:445-446.
    PubMed    


  59. KOHLMANN J, Kirsten H, Simon JC, Ziemer M, et al
    Refined common terminology criteria for adverse events criteria - respective systemic melanoma therapy.
    Melanoma Res. 2019;29:444-445.
    PubMed    


    July 2019
  60. HU H, Li Z, Zhou Y, Zhang Y, et al
    GLT8D1 overexpression as a novel prognostic biomarker in human cutaneous melanoma.
    Melanoma Res. 2019 Jul 11. doi: 10.1097/CMR.0000000000000631.
    PubMed     Abstract available


  61. MALKHASYAN KA, Rooney SL, Snow AN, Swick BL, et al
    The clinical characteristics of melanoma with BRAF V600R mutation: a case series study.
    Melanoma Res. 2019 Jul 11. doi: 10.1097/CMR.0000000000000630.
    PubMed     Abstract available


  62. GUTIERREZ-CASTANEDA LD, Nova JA, Tovar-Parra JD
    Frequency of mutations in BRAF, NRAS, and KIT in different populations and histological subtypes of melanoma: a systemic review.
    Melanoma Res. 2019 Jul 3. doi: 10.1097/CMR.0000000000000628.
    PubMed     Abstract available


    June 2019
  63. ANDERSON KL, Snyder KM, Ito D, Lins DC, et al
    Evolutionarily conserved resistance to phagocytosis observed in melanoma cells is insensitive to upregulation of pro-phagocytic signals and to CD47 blockade.
    Melanoma Res. 2019 Jun 12. doi: 10.1097/CMR.0000000000000629.
    PubMed     Abstract available


  64. STRBENAC D, Wang K, Wang X, Dong J, et al
    Melanoma Explorer: a web application to allow easy reanalysis of publicly available and clinically annotated melanoma omics data sets.
    Melanoma Res. 2019;29:342-344.
    PubMed     Abstract available


  65. PLAQUEVENT M, Greliak A, Pinard C, Duval-Modeste AB, et al
    Simultaneous long-lasting regression of multiple nevi and melanoma metastases after ipilimumab therapy.
    Melanoma Res. 2019;29:311-312.
    PubMed     Abstract available


  66. WILSON MA, Zhong J, Rosenbaum BE, Utter K, et al
    Impact of initial stage on metastatic melanoma survival.
    Melanoma Res. 2019;29:281-288.
    PubMed     Abstract available


  67. MANRIQUE-SILVA E, Reyes-Garcia D, Traves V, Rachakonda S, et al
    TERT promoter mutation subtypes in 20 in-situ melanomas.
    Melanoma Res. 2019;29:347-348.
    PubMed    


  68. FERNANDEZ-DIAZ AB, Garcia-Medina A, Ferrer-Guillen B, Berrocal A, et al
    Eye immune privilege? Nivolumab plus ipilimumab: successful treatment in a patient with cutaneous melanoma and ocular metastases.
    Melanoma Res. 2019;29:345-347.
    PubMed    


  69. FERNANDEZ-SARTORIO C, Alos L, Garcia-Herrera A, Ferrando J, et al
    Multiple primary melanoma with the Meyerson phenomenon in a young patient.
    Melanoma Res. 2019;29:325-327.
    PubMed     Abstract available


  70. GAUCI ML, Boudou P, Squara PA, Delyon J, et al
    Checkpoint inhibitor treatment induces an increase in HbA1c in nondiabetic patients.
    Melanoma Res. 2019;29:328-332.
    PubMed     Abstract available


    May 2019
  71. DIAMANTOPOULOS PT, Lakiotaki E, Kyriakakis G, Gogas H, et al
    New primary melanoma in a patient under triple therapy with vemurafenib, cobimetinib, and atezolizumab for metastatic melanoma.
    Melanoma Res. 2019 May 30. doi: 10.1097/CMR.0000000000000627.
    PubMed     Abstract available


  72. ZULEGER CL, Newton MA, Ma X, Ong IM, et al
    Enrichment of melanoma-associated T cells in 6-thioguanine-resistant T cells from metastatic melanoma patients.
    Melanoma Res. 2019 May 23. doi: 10.1097/CMR.0000000000000625.
    PubMed     Abstract available


  73. KOMINA AV, Palkina NV, Aksenenko MB, Lavrentev SN, et al
    Semaphorin-5A downregulation is associated with enhanced migration and invasion of BRAF-positive melanoma cells under vemurafenib treatment in melanomas with heterogeneous BRAF status.
    Melanoma Res. 2019 May 20. doi: 10.1097/CMR.0000000000000621.
    PubMed     Abstract available


  74. DUGGAN MC, Regan-Fendt K, Olaverria Salavaggione GN, Howard JH, et al
    Neuroblastoma RAS viral oncogene homolog mRNA is differentially spliced to give five distinct isoforms: implications for melanoma therapy.
    Melanoma Res. 2019 May 20. doi: 10.1097/CMR.0000000000000623.
    PubMed     Abstract available


  75. PISTONI M, Tondelli G, Gallo C, Torricelli F, et al
    Exploring metabolic reprogramming in melanoma via acquired resistance to the oxidative phosphorylation inhibitor phenformin.
    Melanoma Res. 2019 May 20. doi: 10.1097/CMR.0000000000000624.
    PubMed     Abstract available


  76. REN Y, Lv Q, Yue W, Liu B, et al
    The programmed cell death protein-1/programmed cell death ligand 1 expression, CD3+ T cell infiltration, NY-ESO-1 expression, and microsatellite instability phenotype in primary cutaneous melanoma and mucosal melanoma and their clinical significance a
    Melanoma Res. 2019 May 14. doi: 10.1097/CMR.0000000000000620.
    PubMed     Abstract available


  77. MENZIES SW, Liyanarachchi S, Coates E, Smith A, et al
    Estimated risk of progression of lentigo maligna to lentigo maligna melanoma.
    Melanoma Res. 2019 May 14. doi: 10.1097/CMR.0000000000000619.
    PubMed     Abstract available


  78. MARTIN-ALGARRA S, Hinshelwood R, Mesnage S, Cebon J, et al
    Effectiveness of dabrafenib in the treatment of patients with BRAF V600-mutated metastatic melanoma in a Named Patient Program.
    Melanoma Res. 2019 May 14. doi: 10.1097/CMR.0000000000000608.
    PubMed     Abstract available


  79. HAGGSTROM L, Duong TA, Thomas B, Brungs D, et al
    Disseminated intravascular coagulation and melanoma: a novel case occurring in metastatic melanoma with BRAF and NRAS mutations and systematic review.
    Melanoma Res. 2019 May 14. doi: 10.1097/CMR.0000000000000622.
    PubMed     Abstract available


  80. NAMIKAWA K, Takahashi A, Mori T, Tsutsumida A, et al
    Nivolumab for patients with metastatic uveal melanoma previously untreated with ipilimumab: a single-institution retrospective study.
    Melanoma Res. 2019 May 14. doi: 10.1097/CMR.0000000000000617.
    PubMed     Abstract available


  81. SCATOZZA F, D'Arcangelo D, Giampietri C, Facchiano F, et al
    Melanogenesis and autophagy in melanoma.
    Melanoma Res. 2019 May 14. doi: 10.1097/CMR.0000000000000615.
    PubMed    


    April 2019
  82. AUTIER P, Dore JF
    Ultraviolet radiation and cutaneous melanoma: a historical perspective.
    Melanoma Res. 2019 Apr 8. doi: 10.1097/CMR.0000000000000609.
    PubMed     Abstract available


  83. KOHLMANN J, Wagenknecht D, Simon JC, Ziemer M, et al
    Immune-related pancreatitis associated with checkpoint blockade in melanoma.
    Melanoma Res. 2019 Apr 5. doi: 10.1097/CMR.0000000000000611.
    PubMed     Abstract available


  84. MARIC H, Supic G, Kandolf-Sekulovic L, Maric V, et al
    DNMT1 and DNMT3B genetic polymorphisms affect the clinical course and outcome of melanoma patients.
    Melanoma Res. 2019 Apr 3. doi: 10.1097/CMR.0000000000000612.
    PubMed     Abstract available


  85. STERA S, Balermpas P, Blanck O, Wolff R, et al
    Stereotactic radiosurgery combined with immune checkpoint inhibitors or kinase inhibitors for patients with multiple brain metastases of malignant melanoma.
    Melanoma Res. 2019;29:187-195.
    PubMed     Abstract available


  86. MAURER DM, Butterfield LH, Vujanovic L
    Melanoma vaccines: clinical status and immune endpoints.
    Melanoma Res. 2019;29:109-118.
    PubMed     Abstract available


    March 2019
  87. NEELAM S, Mellon J, Wilkerson A, Niederkorn JY, et al
    Defective FasL expression is associated with increased resistance to melanoma liver metastases and enhanced natural killer cell activity.
    Melanoma Res. 2019 Mar 29. doi: 10.1097/CMR.0000000000000614.
    PubMed     Abstract available


  88. MIKKELSEN LH, Andersen MK, Andreasen S, Larsen AC, et al
    Global microRNA profiling of metastatic conjunctival melanoma.
    Melanoma Res. 2019 Mar 29. doi: 10.1097/CMR.0000000000000606.
    PubMed     Abstract available


  89. BLANKENSTEIN SA, van Akkooi ACJ
    Adjuvant systemic therapy in high-risk melanoma.
    Melanoma Res. 2019 Mar 20. doi: 10.1097/CMR.0000000000000604.
    PubMed     Abstract available


  90. LIANG L, Zhang Z, Qin X, Gao Y, et al
    Long noncoding RNA ZFAS1 promotes tumorigenesis through regulation of miR-150-5p/RAB9A in melanoma.
    Melanoma Res. 2019 Mar 18. doi: 10.1097/CMR.0000000000000595.
    PubMed     Abstract available


  91. GRATZ V, Langan EA, Neumann A, Zillikens D, et al
    Acute neurological adverse events during immune checkpoint inhibition therapy in patients with melanoma brain metastases.
    Melanoma Res. 2019 Mar 11. doi: 10.1097/CMR.0000000000000597.
    PubMed     Abstract available


  92. ORLANDI E, Chiara Z, Albino P, Morena N, et al
    Lack of association of metastasis-associated lung adenocarcinoma transcript 1 variants with melanoma skin cancer risk.
    Melanoma Res. 2019 Mar 11. doi: 10.1097/CMR.0000000000000605.
    PubMed     Abstract available


  93. MANGANA J, Dimitriou F, Braun R, Ludwig S, et al
    Single-center real-life experience with low-dose ipilimumab monotherapy in adjuvant setting for patients with stage III melanoma.
    Melanoma Res. 2019 Mar 11. doi: 10.1097/CMR.0000000000000593.
    PubMed     Abstract available


  94. OUWERKERK W, van den Berg M, van der Niet S, Limpens J, et al
    Biomarkers, measured during therapy, for response of melanoma patients to immune checkpoint inhibitors: a systematic review.
    Melanoma Res. 2019 Mar 7. doi: 10.1097/CMR.0000000000000589.
    PubMed     Abstract available


  95. MOHN N, Suhs KW, Gingele S, Angela Y, et al
    Acute progressive neuropathy-myositis-myasthenia-like syndrome associated with immune-checkpoint inhibitor therapy in patients with metastatic melanoma.
    Melanoma Res. 2019 Mar 6. doi: 10.1097/CMR.0000000000000598.
    PubMed     Abstract available


  96. KIANMEHR Z, Khorsandi K, Mohammadi M, Hosseinzadeh R, et al
    Low-level laser irradiation potentiates anticancer activity of p-coumaric acid against human malignant melanoma cells.
    Melanoma Res. 2019 Mar 6. doi: 10.1097/CMR.0000000000000603.
    PubMed     Abstract available


  97. NUNES TWN, Filippi-Chiela EC, Callegari-Jacques SM, da Silva VD, et al
    Nuclear morphometric analysis in tissue as an objective tool with potential use to improve melanoma staging.
    Melanoma Res. 2019 Mar 4. doi: 10.1097/CMR.0000000000000594.
    PubMed     Abstract available


  98. SWAMI U, Monga V, Freesmeier M, Zhang W, et al
    Exceptional responses with sequential metronomic temozolomide after pembrolizumab failure in patients with metastatic melanoma.
    Melanoma Res. 2019 Mar 1. doi: 10.1097/CMR.0000000000000592.
    PubMed     Abstract available


    February 2019
  99. DRYSDALE E, Peng Y, Nguyen P, Baetz T, et al
    A population-based study of the treatment effect of first-line ipilimumab for metastatic or unresectable melanoma.
    Melanoma Res. 2019 Feb 14. doi: 10.1097/CMR.0000000000000582.
    PubMed     Abstract available


  100. BLAKEWAY EA, Elshimy N, Muinonen-Martin A, Marples M, et al
    Cutaneous lupus associated with pembrolizumab therapy for advanced melanoma: a report of three cases.
    Melanoma Res. 2019 Feb 11. doi: 10.1097/CMR.0000000000000587.
    PubMed     Abstract available


  101. DAHAL U, Kang L, Gupta M
    RNA m6A methyltransferase METTL3 regulates invasiveness of melanoma cells by matrix metallopeptidase 2.
    Melanoma Res. 2019 Feb 11. doi: 10.1097/CMR.0000000000000580.
    PubMed     Abstract available


  102. SZASZ I, Koroknai V, Kiss T, Vizkeleti L, et al
    Molecular alterations associated with acquired resistance to BRAFV600E targeted therapy in melanoma cells.
    Melanoma Res. 2019 Feb 6. doi: 10.1097/CMR.0000000000000588.
    PubMed     Abstract available


  103. BOSELLO F, Al-Jamal RT, Cohen VML
    Very late recurrence of iris melanoma: 45 years after treatment.
    Melanoma Res. 2019 Feb 5. doi: 10.1097/CMR.0000000000000581.
    PubMed     Abstract available


  104. XU W, Moor RJ, Walpole ET, Atkinson VG, et al
    Pregnancy with successful foetal and maternal outcome in a melanoma patient treated with nivolumab in the first trimester: case report and review of the literature.
    Melanoma Res. 2019 Feb 5. doi: 10.1097/CMR.0000000000000586.
    PubMed     Abstract available


  105. DIMITRIOU F, Mangana J, Micaletto S, Braun RP, et al
    Cytokine release syndrome as an important differential diagnosis of severe skin toxicity with organ damage during switch from immunotherapy to targeted therapy in metastatic melanoma.
    Melanoma Res. 2019;29:107-108.
    PubMed    


  106. YANG J, Price MA, Wanshura LEC, He J, et al
    Chondroitin sulfate proteoglycan 4 enhanced melanoma motility and growth requires a cysteine in the core protein transmembrane domain.
    Melanoma Res. 2019 Feb 1. doi: 10.1097/CMR.0000000000000574.
    PubMed     Abstract available


  107. MIR R, Shaw HM, Nathan PD
    Mycophenolate mofetil alongside high-dose corticosteroids: optimizing the management of combination immune checkpoint inhibitor-induced colitis.
    Melanoma Res. 2019;29:102-106.
    PubMed     Abstract available


  108. SEREMET T, Haccuria A, Lienard D, Del Marmol V, et al
    Anaphylaxis-like reaction to anti-BRAF inhibitor dabrafenib confirmed by drug provocation test.
    Melanoma Res. 2019;29:95-98.
    PubMed     Abstract available


    January 2019
  109. DE GIORGI V, Scarfi F, Gori A, Maida P, et al
    Nevi and Breslow thickness in melanoma: sex differences?
    Melanoma Res. 2019 Jan 30. doi: 10.1097/CMR.0000000000000579.
    PubMed     Abstract available


  110. IACONO D, Basile D, Gerratana L, Vitale MG, et al
    Prognostic role of disease extent and lymphocyte-monocyte ratio in advanced melanoma.
    Melanoma Res. 2019 Jan 29. doi: 10.1097/CMR.0000000000000584.
    PubMed     Abstract available


  111. STENEHJEM DD, Au TH, Ngorsuraches S, Ma J, et al
    Immunotargeted therapy in melanoma: patient, provider preferences, and willingness to pay at an academic cancer center.
    Melanoma Res. 2019 Jan 25. doi: 10.1097/CMR.0000000000000572.
    PubMed     Abstract available


  112. MARASIGAN V, Guvenc C, van den Oord JJ, Stas M, et al
    Melanoma susceptibility variant rs869330 in the MTAP gene is associated with melanoma outcome.
    Melanoma Res. 2019 Jan 23. doi: 10.1097/CMR.0000000000000578.
    PubMed     Abstract available


  113. GONG HZ, Zheng HY, Li J
    Amelanotic melanoma.
    Melanoma Res. 2019 Jan 21. doi: 10.1097/CMR.0000000000000571.
    PubMed     Abstract available


  114. RANTALA ES, Hernberg M, Kivela TT
    Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis.
    Melanoma Res. 2019 Jan 16. doi: 10.1097/CMR.0000000000000575.
    PubMed     Abstract available


  115. JAARSMA-COES MG, Goncalves Ferreira TA, van Haren GR, Marinkovic M, et al
    MRI enables accurate diagnosis and follow-up in uveal melanoma patients after vitrectomy.
    Melanoma Res. 2019 Jan 16. doi: 10.1097/CMR.0000000000000568.
    PubMed     Abstract available


  116. PAN B, Lin X, Zhang L, Hong W, et al
    Long noncoding RNA X-inactive specific transcript promotes malignant melanoma progression and oxaliplatin resistance.
    Melanoma Res. 2019 Jan 11. doi: 10.1097/CMR.0000000000000560.
    PubMed     Abstract available


  117. YANG Y, Zhe H, Massoumi R, Ke H, et al
    Decreased expression of nemo-like kinase in melanoma is correlated with increased vascularity and metastasis.
    Melanoma Res. 2019 Jan 10. doi: 10.1097/CMR.0000000000000576.
    PubMed     Abstract available


  118. KHURANA S, Baldeo C, Joseph RW
    Inositol hexaphosphate plus inositol induced complete remission in stage IV melanoma: a case report.
    Melanoma Res. 2019 Jan 5. doi: 10.1097/CMR.0000000000000577.
    PubMed     Abstract available


  119. MOTOFEI IG
    Melanoma and autoimmunity: spontaneous regressions as a possible model for new therapeutic approaches.
    Melanoma Res. 2019 Jan 4. doi: 10.1097/CMR.0000000000000573.
    PubMed     Abstract available


  120. TIO D, Kasiem FR, Willemsen M, van Doorn R, et al
    Expression of cancer/testis antigens in cutaneous melanoma: a systematic review.
    Melanoma Res. 2019 Jan 4. doi: 10.1097/CMR.0000000000000569.
    PubMed     Abstract available


  121. MANCINI S, Crocetti E, Bucchi L, Pimpinelli N, et al
    Time trends and age-period-cohort analysis of cutaneous malignant melanoma incidence rates in the Romagna Region (northern Italy), 1986-2014.
    Melanoma Res. 2019 Jan 4. doi: 10.1097/CMR.0000000000000570.
    PubMed     Abstract available


    December 2018
  122. BAFALOUKOS D, Papaxoinis G, Linardou H, Diamantopoulos P, et al
    Prognostic significance of distant metastasis-free interval in patients with relapsed melanoma treated with BRAF with or without MEK inhibitors.
    Melanoma Res. 2018 Dec 28. doi: 10.1097/CMR.0000000000000562.
    PubMed     Abstract available


  123. LEE WJ, Lee MH, Kim HT, Won CH, et al
    Prognostic significance of CD163 expression and its correlation with cyclooxygenase-2 and vascular endothelial growth factor expression in cutaneous melanoma.
    Melanoma Res. 2018 Dec 19. doi: 10.1097/CMR.0000000000000549.
    PubMed     Abstract available


  124. CRINCOLI E, Moliterni E, Catania F, Didona D, et al
    Correlation of serum tryptase levels with total number of nevi, Breslow thickness, ulceration, and mitotic index in melanoma patients: evaluation of a promising prognostic marker.
    Melanoma Res. 2018 Dec 15. doi: 10.1097/CMR.0000000000000561.
    PubMed     Abstract available


  125. BOURSI B, Werner TJ, Gholami S, Margalit O, et al
    Physiologic colonic fluorine-18-fluorodeoxyglucose uptake may predict response to immunotherapy in patients with metastatic melanoma.
    Melanoma Res. 2018 Dec 14. doi: 10.1097/CMR.0000000000000566.
    PubMed     Abstract available


  126. OTTES VASCONCELOS R, Serini S, de Souza Votto AP, Santos Trindade G, et al
    Combination of omega-3 fatty acids and cisplatin as a potential alternative strategy for personalized therapy of metastatic melanoma: an in-vitro study.
    Melanoma Res. 2018 Dec 13. doi: 10.1097/CMR.0000000000000564.
    PubMed     Abstract available


  127. MAHAPATRA L, Andruska N, Mao C, Gruber SB, et al
    Protein kinase C-alpha is upregulated by IMP1 in melanoma and is linked to poor survival.
    Melanoma Res. 2018 Dec 12. doi: 10.1097/CMR.0000000000000558.
    PubMed     Abstract available


  128. CORAZZA M, Dika E, Maietti E, Musmeci D, et al
    Eruptive cherry angiomas and skin melanoma: a fortuitous association?
    Melanoma Res. 2018 Dec 12. doi: 10.1097/CMR.0000000000000563.
    PubMed     Abstract available


  129. BLOCK MS, Nevala WK, Pang YP, Allred JB, et al
    A pilot clinical trial testing topical resiquimod and a xenopeptide as immune adjuvants for a melanoma vaccine targeting MART-1.
    Melanoma Res. 2018 Dec 4. doi: 10.1097/CMR.0000000000000556.
    PubMed     Abstract available


  130. CIMMINIELLO C, Indini A, Di Guardo L, Prisciandaro M, et al
    Pembrolizumab in the treatment of advanced/metastatic melanoma: a single-center institution experience.
    Melanoma Res. 2018 Dec 4. doi: 10.1097/CMR.0000000000000539.
    PubMed     Abstract available



  131. A unique gene expression signature is significantly differentially expressed in tumor-positive or tumor-negative sentinel lymph nodes in patients with melanoma: Erratum.
    Melanoma Res. 2018;28:655.
    PubMed    


    November 2018
  132. DISANO JA, Huffnagle I, Gowda R, Spiegelman VS, et al
    Loss of miR-155 upregulates WEE1 in metastatic melanoma.
    Melanoma Res. 2018 Nov 29. doi: 10.1097/CMR.0000000000000545.
    PubMed     Abstract available


  133. YANG J, Chen S, Li Y, Wang B, et al
    Incidence rate and risk factors for suicide death in patients with skin malignant melanoma: a Surveillance, Epidemiology, and End Results analysis.
    Melanoma Res. 2018 Nov 26. doi: 10.1097/CMR.0000000000000559.
    PubMed     Abstract available


  134. YAN J, Xu L, Yu J, Wu X, et al
    Prognostic role of NRAS isoforms in Chinese melanoma patients.
    Melanoma Res. 2018 Nov 26. doi: 10.1097/CMR.0000000000000557.
    PubMed     Abstract available


  135. BIANCONI F, Crocetti E, Grisci C, Primieri C, et al
    What has changed in the epidemiology of skin melanoma in central Italy during the past 20 years?
    Melanoma Res. 2018 Nov 26. doi: 10.1097/CMR.0000000000000551.
    PubMed     Abstract available


  136. HU Y, Wang Q, Zhu XH
    MiR-135b is a novel oncogenic factor in cutaneous melanoma by targeting LATS2.
    Melanoma Res. 2018 Nov 21. doi: 10.1097/CMR.0000000000000524.
    PubMed     Abstract available


  137. SARUBI HC, Pereira NB, Gomes CC, Gomez RS, et al
    Molecular and immunohistochemical analyses of uveal melanoma patient cohort.
    Melanoma Res. 2018 Nov 21. doi: 10.1097/CMR.0000000000000523.
    PubMed     Abstract available


  138. WU K, Wang W, Ye Y, Huang J, et al
    Integration of protein interaction and gene co-expression information for identification of melanoma candidate genes.
    Melanoma Res. 2018 Nov 19. doi: 10.1097/CMR.0000000000000525.
    PubMed     Abstract available


  139. ROMANO S, D'Arrigo P, Tufano M, Staibano S, et al
    TRAF2 and FKBP51 as possible markers for identification of suitable melanoma tumors for tumor necrosis factor-alpha inhibition.
    Melanoma Res. 2018 Nov 19. doi: 10.1097/CMR.0000000000000553.
    PubMed     Abstract available


  140. URBONAS V, Smailyte G, Urbonaite GV, Dulskas A, et al
    Natural killer cell-based immunotherapy: a new fighter against melanoma?
    Melanoma Res. 2018 Nov 19. doi: 10.1097/CMR.0000000000000552.
    PubMed     Abstract available


  141. MASCITTI M, Santarelli A, Sartini D, Rubini C, et al
    Analysis of nicotinamide N-methyltransferase in oral malignant melanoma and potential prognostic significance.
    Melanoma Res. 2018 Nov 13. doi: 10.1097/CMR.0000000000000548.
    PubMed     Abstract available


  142. DUNDR P, Simon K, Nemejcova K, Bartu M, et al
    Stathmin is a potential therapeutic target but not a prognostic marker in melanoma: an immunohistochemical study of 323 melanocytic lesions.
    Melanoma Res. 2018 Nov 12. doi: 10.1097/CMR.0000000000000550.
    PubMed     Abstract available


  143. SALMI S, Siiskonen H, Sironen R, Tyynela-Korhonen K, et al
    The number and localization of CD68+ and CD163+ macrophages in different stages of cutaneous melanoma.
    Melanoma Res. 2018 Nov 5. doi: 10.1097/CMR.0000000000000522.
    PubMed     Abstract available


  144. YANG N, Lu J, Lu Y, Guo J, et al
    Primary malignant melanotic melanoma and hypomelanotic melanoma of the female urethra: case series and a review of the literature in China.
    Melanoma Res. 2018 Nov 2. doi: 10.1097/CMR.0000000000000521.
    PubMed     Abstract available


  145. SACHPEKIDIS C, Kopp-Schneider A, Hakim-Meibodi L, Dimitrakopoulou-Strauss A, et al
    18F-FDG PET/CT longitudinal studies in patients with advanced metastatic melanoma for response evaluation of combination treatment with vemurafenib and ipilimumab.
    Melanoma Res. 2018 Nov 1. doi: 10.1097/CMR.0000000000000541.
    PubMed     Abstract available


    October 2018
  146. PEPIN F, Julien AS, Fugaru I, Lihimdi N, et al
    Regression rate of choroidal melanoma following iodine-125 brachytherapy is not associated with metastatic spread.
    Melanoma Res. 2018 Oct 31. doi: 10.1097/CMR.0000000000000540.
    PubMed     Abstract available


  147. ABBOTT JL, Qureshi MM, Truong MT, Sahni D, et al
    Comparing survival outcomes in early stage desmoplastic melanoma with or without adjuvant radiation.
    Melanoma Res. 2018 Oct 31. doi: 10.1097/CMR.0000000000000532.
    PubMed     Abstract available


  148. ZHANG D, Wang Z, Shang D, Yu J, et al
    Incidence and prognosis of brain metastases in cutaneous melanoma patients: a population-based study.
    Melanoma Res. 2018 Oct 30. doi: 10.1097/CMR.0000000000000538.
    PubMed     Abstract available


  149. DRAGO JZ, Lawrence D, Livingstone E, Zimmer L, et al
    Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: a real-life multicenter study.
    Melanoma Res. 2018 Oct 29. doi: 10.1097/CMR.0000000000000527.
    PubMed     Abstract available


  150. BUYUKKAPU BAY S, Kebudi R, Zulfikar B
    Cutaneous adverse event associated with vemurafenib in a 3-year-old pediatric patient with BRAF mutation-positive metastatic melanoma and factor X deficiency.
    Melanoma Res. 2018 Oct 29. doi: 10.1097/CMR.0000000000000537.
    PubMed     Abstract available


  151. VUJIC I, Gandini S, Stanganelli I, Fierro MT, et al
    A meta-analysis of melanoma risk in industrial workers.
    Melanoma Res. 2018 Oct 26. doi: 10.1097/CMR.0000000000000531.
    PubMed     Abstract available


  152. MARCOVAL J, Sabate-Llobera A, Bermejo J, Fornons-Servent R, et al
    Hibernoma as an incidental finding in the 18F-FDG PET/CT of a patient with melanoma.
    Melanoma Res. 2018 Oct 24. doi: 10.1097/CMR.0000000000000530.
    PubMed     Abstract available


  153. ABDEL-RAHMAN O
    Population-based validation of the National Cancer Comprehensive Network recommendations for baseline imaging workup of cutaneous melanoma.
    Melanoma Res. 2018 Oct 22. doi: 10.1097/CMR.0000000000000528.
    PubMed     Abstract available


  154. BELLOCQ D, Roy P, Kodjikian L, Mathis T, et al
    20-year assessment of metastatic latency and subsequent time to death after proton therapy for uveal melanomas.
    Melanoma Res. 2018 Oct 12. doi: 10.1097/CMR.0000000000000519.
    PubMed     Abstract available


  155. VAN LAAR RK, Lincoln MT, van Laar BJ
    A plasma microRNA biomarker of melanoma as a personalised assessment of treatment response.
    Melanoma Res. 2018 Oct 12. doi: 10.1097/CMR.0000000000000492.
    PubMed     Abstract available


  156. PETRELLI F, Ardito R, Merelli B, Lonati V, et al
    Prognostic and predictive role of elevated lactate dehydrogenase in patients with melanoma treated with immunotherapy and BRAF inhibitors: a systematic review and meta-analysis.
    Melanoma Res. 2018 Oct 10. doi: 10.1097/CMR.0000000000000520.
    PubMed     Abstract available


  157. DABROSIN N, Sloth Juul K, Baehr Georgsen J, Andrup S, et al
    Innate immune cell infiltration in melanoma metastases affects survival and is associated with BRAFV600E mutation status.
    Melanoma Res. 2018 Oct 5. doi: 10.1097/CMR.0000000000000515.
    PubMed     Abstract available


  158. LASKE J, Meier F, Bauer A, Beissert S, et al
    Tattoo-associated complications of metastatic melanoma treated with dabrafenib and trametinib.
    Melanoma Res. 2018;28:485-487.
    PubMed    


    September 2018
  159. HALFPENNY NJA, Scott DA, Thompson JC, Gurung B, et al
    A practical approach to predict expansion of evidence networks: a case study in treatment-naive advanced melanoma.
    Melanoma Res. 2018 Sep 29. doi: 10.1097/CMR.0000000000000513.
    PubMed     Abstract available


  160. HWANG SJE, Park JJW, Wakade D, Chou S, et al
    Cutaneous adverse events of anti-programmed death 1 antibodies combined with anti-cytotoxic T-lymphocyte-associated protein 4 therapy use in patients with metastatic melanoma.
    Melanoma Res. 2018 Sep 29. doi: 10.1097/CMR.0000000000000518.
    PubMed     Abstract available


  161. YIP RHL, Lee LH, Schaeffer DF, Horst BA, et al
    Lymphocytic gastritis induced by pembrolizumab in a patient with metastatic melanoma.
    Melanoma Res. 2018 Sep 25. doi: 10.1097/CMR.0000000000000502.
    PubMed     Abstract available


  162. YIN G, Guo W, Chen X, Huang Z, et al
    Prognosis of endoscopic surgery and traditional open resection in mucosal melanoma of the nasal cavity and paranasal sinus.
    Melanoma Res. 2018 Sep 25. doi: 10.1097/CMR.0000000000000516.
    PubMed     Abstract available


  163. GHATE S, Ionescu-Ittu R, Burne R, Ndife B, et al
    Patterns of treatment and BRAF testing with immune checkpoint inhibitors and targeted therapy in patients with metastatic melanoma presumed to be BRAF positive.
    Melanoma Res. 2018 Sep 21. doi: 10.1097/CMR.0000000000000504.
    PubMed     Abstract available


  164. SCAINI MC, Pigozzo J, Pizzi M, Manicone M, et al
    Clonal heterogeneity of melanoma in a paradigmatic case study: future prospects for circulating melanoma cells.
    Melanoma Res. 2018 Sep 14. doi: 10.1097/CMR.0000000000000510.
    PubMed     Abstract available


  165. TINGFENG X, Fuqiang P, Dong L
    Expression and clinical significance of S100 family genes in patients with melanoma.
    Melanoma Res. 2018 Sep 13. doi: 10.1097/CMR.0000000000000512.
    PubMed     Abstract available


  166. TARHINI A, Ghate SR, Ionescu-Ittu R, Manceur AM, et al
    Postsurgical treatment landscape and economic burden of locoregional and distant recurrence in patients with operable nonmetastatic melanoma.
    Melanoma Res. 2018 Sep 13. doi: 10.1097/CMR.0000000000000507.
    PubMed     Abstract available


  167. SHAH S, Luke JJ, Jacene HA, Chen T, et al
    Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma.
    Melanoma Res. 2018 Sep 11. doi: 10.1097/CMR.0000000000000509.
    PubMed     Abstract available


  168. SEREMET T, Planken S, Schwarze JK, Jansen Y, et al
    Successful treatment with intralesional talimogene laherparepvec in two patients with immune checkpoint inhibitors refractory advanced melanoma.
    Melanoma Res. 2018 Sep 11. doi: 10.1097/CMR.0000000000000501.
    PubMed     Abstract available


  169. CHRISTENSEN L, Scott J, Bordeaux J
    Use of gene expression profile testing as a prognostic tool in early-stage cutaneous melanoma - compelling but not ready for primetime.
    Melanoma Res. 2018 Sep 11. doi: 10.1097/CMR.0000000000000506.
    PubMed     Abstract available


  170. DE MELO AC, Wainstein AJA, Buzaid AC, Thuler LCS, et al
    Melanoma signature in Brazil: epidemiology, incidence, mortality, and trend lessons from a continental mixed population country in the past 15 years.
    Melanoma Res. 2018 Sep 10. doi: 10.1097/CMR.0000000000000511.
    PubMed     Abstract available


  171. ZHAO B, Cheng X, Zhou X
    The BET-bromodomain inhibitor JQ1 mitigates vemurafenib drug resistance in melanoma.
    Melanoma Res. 2018 Sep 5. doi: 10.1097/CMR.0000000000000497.
    PubMed     Abstract available


  172. TROMME I, Sacre L, Hammouch F, Richez P, et al
    Melanoma diagnosis: predictive value of macroscopic changes observed by the patient.
    Melanoma Res. 2018 Sep 5. doi: 10.1097/CMR.0000000000000496.
    PubMed     Abstract available


  173. NYE A, Collins JD, Porter CL, Montes de Oca M, et al
    Predictive genetic profiles for regional lymph node metastasis in primary cutaneous melanoma: a case-matched pilot study.
    Melanoma Res. 2018 Sep 1. doi: 10.1097/CMR.0000000000000499.
    PubMed     Abstract available


    August 2018
  174. KANG R, Lipner S
    Assessment of internet sources on subungual melanoma.
    Melanoma Res. 2018 Aug 30. doi: 10.1097/CMR.0000000000000508.
    PubMed     Abstract available


  175. TAN SY, Najita J, Li X, Strazzulla LC, et al
    Clinicopathologic features correlated with paradoxical outcomes in stage IIC versus IIIA melanoma patients.
    Melanoma Res. 2018 Aug 30. doi: 10.1097/CMR.0000000000000483.
    PubMed     Abstract available


  176. DIAMANTOPOULOS PT, Stoungioti S, Anastasopoulou A, Papaxoinis G, et al
    Incomplete Vogt-Koyanagi-Harada disease following treatment with encorafenib and binimetinib for metastatic melanoma.
    Melanoma Res. 2018 Aug 30. doi: 10.1097/CMR.0000000000000505.
    PubMed     Abstract available


  177. SWORDS DS, Andtbacka RHI, Bowles TL, Hyngstrom JR, et al
    Routine retrieval of pelvic sentinel lymph nodes for melanoma rarely adds prognostic information or alters management.
    Melanoma Res. 2018 Aug 29. doi: 10.1097/CMR.0000000000000498.
    PubMed     Abstract available


  178. KENESSEY I, Kramer Z, Istvan L, Cserepes MT, et al
    Inhibition of epidermal growth factor receptor improves antitumor efficacy of vemurafenib in BRAF-mutant human melanoma in preclinical model.
    Melanoma Res. 2018 Aug 17. doi: 10.1097/CMR.0000000000000488.
    PubMed     Abstract available


  179. HERBERT A, Koo MM, Barclay ME, Greenberg DC, et al
    Stage-specific incidence trends of melanoma in an English region, 1996-2015: longitudinal analyses of population-based data.
    Melanoma Res. 2018 Aug 13. doi: 10.1097/CMR.0000000000000489.
    PubMed     Abstract available


  180. YAN J, Wu X, Yu J, Ma M, et al
    Establishment and characterization of melanoma patient-derived xenograft models for preclinical evaluation of novel therapeutics.
    Melanoma Res. 2018 Aug 6. doi: 10.1097/CMR.0000000000000494.
    PubMed     Abstract available


  181. GROGAN N, Swami U, Bossler AD, Zakharia Y, et al
    Toxicities with targeted therapies after immunotherapy in metastatic melanoma.
    Melanoma Res. 2018 Aug 6. doi: 10.1097/CMR.0000000000000493.
    PubMed     Abstract available


  182. LIU G, Wang Y, Fei F, Wang X, et al
    Clinical characteristics and preliminary morphological observation of 47 cases of primary anorectal malignant melanomas.
    Melanoma Res. 2018 Aug 3. doi: 10.1097/CMR.0000000000000491.
    PubMed     Abstract available


  183. MONTAUDIE H, Picard A, Panaia-Ferrari P, Boukari F, et al
    Painful acute thyroiditis following a first cure of Ipilimumab plus Nivolumab for metastatic melanoma.
    Melanoma Res. 2018;28:368-369.
    PubMed    


    July 2018
  184. NICHOLAS MN, Khoja L, Atenafu EG, Hogg D, et al
    Prognostic factors for first-line therapy and overall survival of metastatic uveal melanoma: The Princess Margaret Cancer Centre experience.
    Melanoma Res. 2018 Jul 31. doi: 10.1097/CMR.0000000000000468.
    PubMed     Abstract available


  185. SUN H, Chen Y, Chen Y, Liu D, et al
    Primary malignant melanoma of the cervix: 14 cases and literature overview.
    Melanoma Res. 2018 Jul 23. doi: 10.1097/CMR.0000000000000469.
    PubMed     Abstract available


  186. AYDOGMUS-OZTURK F, Gunaydin K, Ozturk M, Jahan H, et al
    Effect of Sideritis leptoclada against HT-144 human malignant melanoma.
    Melanoma Res. 2018 Jul 19. doi: 10.1097/CMR.0000000000000487.
    PubMed     Abstract available


  187. SAGLAM O, Naqvi SMH, Zhang Y, Mesa T, et al
    Female genitourinary tract melanoma: mutation analysis with clinicopathologic correlation: a single-institution experience.
    Melanoma Res. 2018 Jul 19. doi: 10.1097/CMR.0000000000000480.
    PubMed     Abstract available


  188. BORGOGNONI L, Bellucci F, Urso C, Manneschi G, et al
    Enhancing the prognostic role of melanoma sentinel lymph nodes through microscopic tumour burden characterization: clinical usefulness in patients who do not undergo complete lymph node dissection.
    Melanoma Res. 2018 Jul 17. doi: 10.1097/CMR.0000000000000481.
    PubMed     Abstract available


  189. NUNES LF, Quintella Mendes GL, Koifman RJ
    Acral melanoma: a retrospective cohort from the Brazilian National Cancer Institute (INCA).
    Melanoma Res. 2018 Jul 16. doi: 10.1097/CMR.0000000000000476.
    PubMed     Abstract available


  190. OLAVERRIA SALAVAGGIONE GN, Duggan MC, Carson WE
    Analysis of MLN4924 (pevonedistat) as a potential therapeutic agent in malignant melanoma.
    Melanoma Res. 2018 Jul 16. doi: 10.1097/CMR.0000000000000474.
    PubMed     Abstract available


  191. BRUNSSEN A, Jansen L, Eisemann N, Waldmann A, et al
    Long-term relative survival from melanoma in Germany 1997-2013.
    Melanoma Res. 2018 Jul 16. doi: 10.1097/CMR.0000000000000482.
    PubMed     Abstract available


  192. HUTCHINSON PE, Halsall JA, Popovici S, Papadogeorgakis E, et al
    Compromised vitamin D receptor signalling in malignant melanoma is associated with tumour progression and mitogen-activated protein kinase activity.
    Melanoma Res. 2018 Jul 12. doi: 10.1097/CMR.0000000000000475.
    PubMed     Abstract available


  193. FERRIS LK, Gerami P, Skelsey MK, Peck G, et al
    Real-world performance and utility of a noninvasive gene expression assay to evaluate melanoma risk in pigmented lesions.
    Melanoma Res. 2018 Jul 12. doi: 10.1097/CMR.0000000000000478.
    PubMed     Abstract available


  194. LYTH J
    Conditional recurrence-free survival in patients with primary stage I-II cutaneous malignant melanoma - a population-based study.
    Melanoma Res. 2018 Jul 9. doi: 10.1097/CMR.0000000000000479.
    PubMed     Abstract available


  195. LAMIAUX M, Scalbert C, Lepesant P, Desmedt E, et al
    Severe skin toxicity with organ damage under the combination of targeted therapy following immunotherapy in metastatic melanoma.
    Melanoma Res. 2018 Jul 6. doi: 10.1097/CMR.0000000000000472.
    PubMed     Abstract available


  196. GORLOV I, Orlow I, Ringelberg C, Hernando E, et al
    Identification of gene expression levels in primary melanoma associated with clinically meaningful characteristics.
    Melanoma Res. 2018 Jul 2. doi: 10.1097/CMR.0000000000000473.
    PubMed     Abstract available


  197. GOMEZ-LEON N, Pacheco-Barcia V, Ballesteros AI, Fraga J, et al
    Skeletal muscle and solitary bone metastases from malignant melanoma: multimodality imaging and oncological outcome.
    Melanoma Res. 2018 Jul 2. doi: 10.1097/CMR.0000000000000466.
    PubMed     Abstract available


    June 2018
  198. URBONAS V, Smailyte G
    Combination of cytokine-directed and anti-programmed cell death protein 1 therapy - a new attractive option in melanoma treatment?
    Melanoma Res. 2018 Jun 29. doi: 10.1097/CMR.0000000000000470.
    PubMed     Abstract available


  199. RAMBHIA PH, Honda K, Arbesman J
    Nivolumab induced inflammation of seborrheic keratoses: a novel cutaneous manifestation in a metastatic melanoma patient.
    Melanoma Res. 2018 Jun 29. doi: 10.1097/CMR.0000000000000477.
    PubMed     Abstract available


  200. MENSHAWY A, Eltonob AA, Barkat SA, Ghanem A, et al
    Nivolumab monotherapy or in combination with ipilimumab for metastatic melanoma: systematic review and meta-analysis of randomized-controlled trials.
    Melanoma Res. 2018 Jun 27. doi: 10.1097/CMR.0000000000000467.
    PubMed     Abstract available


  201. PUZA CJ, Barbas AS, Mosca PJ
    Outcomes of patients with a pretransplant history of early-stage melanoma.
    Melanoma Res. 2018 Jun 25. doi: 10.1097/CMR.0000000000000471.
    PubMed     Abstract available


  202. MORGADO-CARRASCO D, Moreno-Rivera N, Fusta-Novell X, Garcia-Herrera A, et al
    Histiocytoid Sweet's syndrome during combined therapy with BRAF and MEK inhibitors for metastatic melanoma.
    Melanoma Res. 2018;28:256-257.
    PubMed    


    May 2018
  203. HAFLIGER EM, Ramelyte E, Mangana J, Kunz M, et al
    Metastatic acral lentiginous melanoma in a tertiary referral center in Switzerland: a systematic analysis.
    Melanoma Res. 2018 May 29. doi: 10.1097/CMR.0000000000000465.
    PubMed     Abstract available


  204. IACONO D, Cinausero M, Gerratana L, Angione V, et al
    Tumour-infiltrating lymphocytes, programmed death ligand 1 and cyclooxygenase-2 expression in skin melanoma of elderly patients: clinicopathological correlations.
    Melanoma Res. 2018 May 22. doi: 10.1097/CMR.0000000000000462.
    PubMed     Abstract available


  205. BRUTTING J, Bergmann M, Garzarolli M, Rauschenberg R, et al
    Unmet information needs of patients with melanoma in Germany.
    Melanoma Res. 2018 May 21. doi: 10.1097/CMR.0000000000000464.
    PubMed     Abstract available


  206. TETERYCZ P, Jagodzinska-Mucha P, Cybulska-Stopa B, Mariuk-Jarema A, et al
    High baseline neutrophil-to-lymphocyte ratio predicts worse outcome in patients with metastatic BRAF-positive melanoma treated with BRAF and MEK inhibitors.
    Melanoma Res. 2018 May 18. doi: 10.1097/CMR.0000000000000461.
    PubMed     Abstract available


  207. FACINA AS, Facina G, Guerreiro da Silva IDC, Correa SAA, et al
    Pregnancy and the apoptotic pathway in experimental melanoma.
    Melanoma Res. 2018 May 17. doi: 10.1097/CMR.0000000000000452.
    PubMed     Abstract available


  208. ZHOU X, Zeng Y, Jiang H, Xia L, et al
    Predictive value of excision repair cross-complementing group 2 gene Lys751Gln and Asp312Asn polymorphisms in melanoma risk.
    Melanoma Res. 2018 May 15. doi: 10.1097/CMR.0000000000000463.
    PubMed     Abstract available


  209. TSOUTSOS D, Papadopoulos S, Kehagias G, Mara A, et al
    Epidemiological trends in the diagnosis of melanoma in a Southern European population: analysis of a large database from a tertiary referral center.
    Melanoma Res. 2018 May 14. doi: 10.1097/CMR.0000000000000456.
    PubMed     Abstract available


  210. AFZAL MZ, Shirai K
    Immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy alone versus immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy in combination with anti-RANKL denosumuab in malignant melanoma: a retrospective analysis at a tertiary care center.
    Melanoma Res. 2018 May 10. doi: 10.1097/CMR.0000000000000459.
    PubMed     Abstract available


  211. TENGDA L, Shuping L, Mingli G, Jie G, et al
    Serum exosomal microRNAs as potent circulating biomarkers for melanoma.
    Melanoma Res. 2018 May 10. doi: 10.1097/CMR.0000000000000450.
    PubMed     Abstract available


  212. ASCIERTO PA, Bastholt L, Ferrucci PF, Hansson J, et al
    The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma: results from a European expert panel study.
    Melanoma Res. 2018 May 10. doi: 10.1097/CMR.0000000000000455.
    PubMed     Abstract available


  213. MOSHE M, Levi A, Ad-El D, Ben-Amitai D, et al
    Malignant melanoma clinically mimicking pyogenic granuloma: comparison of clinical evaluation and histopathology.
    Melanoma Res. 2018 May 10. doi: 10.1097/CMR.0000000000000451.
    PubMed     Abstract available


  214. SCHOUWENBURG MG, Jochems A, Leeneman B, Franken MG, et al
    Vemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: prognostic factors associated with clinical outcomes.
    Melanoma Res. 2018 May 10. doi: 10.1097/CMR.0000000000000453.
    PubMed     Abstract available


  215. GONG HZ, Zheng HY, Li J
    The clinical significance of KIT mutations in melanoma: a meta-analysis.
    Melanoma Res. 2018 May 9. doi: 10.1097/CMR.0000000000000454.
    PubMed     Abstract available


    April 2018
  216. SEBESTYEN T, Mohos A, Liszkay G, Somlai B, et al
    Correlation with lymphocyte infiltration, but lack of prognostic significance of MECA-79-positive high endothelial venules in primary malignant melanoma.
    Melanoma Res. 2018 Apr 20. doi: 10.1097/CMR.0000000000000457.
    PubMed     Abstract available


  217. LEE WJ, Lee YJ, Shin HJ, Won CH, et al
    Clinicopathological significance of tumor-infiltrating lymphocytes and programmed death-1 expression in cutaneous melanoma: a comparative study on clinical subtypes.
    Melanoma Res. 2018 Apr 9. doi: 10.1097/CMR.0000000000000449.
    PubMed     Abstract available


  218. SIA DIT, Thaung C, O'Hanlon-Brown C, Cohen VML, et al
    Immune privilege: failure of immunotherapy in controlling metastatic cutaneous melanoma to the eye.
    Melanoma Res. 2018 Apr 9. doi: 10.1097/CMR.0000000000000443.
    PubMed     Abstract available


  219. BASSOLI S, Pellegrini C, Longo C, Di Nardo L, et al
    Clinical, dermoscopic, and confocal features of nevi and melanomas in a multiple primary melanoma patient with the MITF p.E318K homozygous mutation.
    Melanoma Res. 2018;28:166-169.
    PubMed    


  220. TAKAHASHI A, Tsutsumida A, Namikawa K, Yamazaki N, et al
    Fulminant type 1 diabetes associated with nivolumab in a patient with metastatic melanoma.
    Melanoma Res. 2018;28:159-160.
    PubMed    


  221. FERNANDEZ-SARTORIO C, Boada A, Chavez-Bourgeois MM, Ruiz Ares GJ, et al
    Aged-looking skin and encorafenib: an adverse event of BRAF inhibitors.
    Melanoma Res. 2018;28:160-162.
    PubMed    


  222. MUTO Y, Ng W, Namikawa K, Takahashi A, et al
    Success of rechallenging dabrafenib and trametinib combination therapy after trametinib-induced rhabdomyolysis: a case report.
    Melanoma Res. 2018;28:151-154.
    PubMed     Abstract available


    March 2018
  223. TURNER KA, Manouchehri JM, Kalafatis M
    Sensitization of recombinant human tumor necrosis factor-related apoptosis-inducing ligand-resistant malignant melanomas by quercetin.
    Melanoma Res. 2018 Mar 28. doi: 10.1097/CMR.0000000000000447.
    PubMed     Abstract available


  224. TERNOV NK, Lambine TL, Wagenblast ALH, Clasen-Linde E, et al
    Targeted ultrasound and fine-needle aspiration cytology for sentinel node diagnostics in early-stage melanoma: a validation study.
    Melanoma Res. 2018 Mar 27. doi: 10.1097/CMR.0000000000000448.
    PubMed     Abstract available


  225. CHESNEY J, Imbert-Fernandez Y, Telang S, Baum M, et al
    Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors.
    Melanoma Res. 2018 Mar 21. doi: 10.1097/CMR.0000000000000444.
    PubMed     Abstract available


  226. KLEEMANN J, Hrgovic I, Ter-Nedden J, Kleimann P, et al
    Fatty acid receptor GPR120: a novel marker for human melanoma.
    Melanoma Res. 2018 Mar 21. doi: 10.1097/CMR.0000000000000445.
    PubMed     Abstract available


  227. LADE-KELLER J, Yuusufi S, Riber-Hansen R, Steiniche T, et al
    Telomerase reverse transcriptase promoter mutations and solar elastosis in cutaneous melanoma.
    Melanoma Res. 2018 Mar 21. doi: 10.1097/CMR.0000000000000446.
    PubMed     Abstract available


  228. NASARRE P, Bonilla IV, Metcalf JS, Hilliard EG, et al
    TRAF3-interacting protein 3, a new oncotarget, promotes tumor growth in melanoma.
    Melanoma Res. 2018 Mar 16. doi: 10.1097/CMR.0000000000000440.
    PubMed     Abstract available


  229. GESKIN LJ, Damiano JJ, Patrone CC, Butterfield LH, et al
    Three antigen-loading methods in dendritic cell vaccines for metastatic melanoma.
    Melanoma Res. 2018 Mar 14. doi: 10.1097/CMR.0000000000000441.
    PubMed     Abstract available


  230. DE UNAMUNO B, Garcia-Casado Z, Banuls J, Requena C, et al
    CDKN2A germline alterations in melanoma patients with personal or familial history of pancreatic cancer.
    Melanoma Res. 2018 Mar 14. doi: 10.1097/CMR.0000000000000442.
    PubMed     Abstract available


  231. STOWMAN AM, Hickman AW, Mauldin IS, Mahmutovic A, et al
    Lymphoid aggregates in desmoplastic melanoma have features of tertiary lymphoid structures.
    Melanoma Res. 2018 Mar 13. doi: 10.1097/CMR.0000000000000439.
    PubMed     Abstract available


  232. FOLEY KC, Nishimura MI, Moore TV
    Combination immunotherapies implementing adoptive T-cell transfer for advanced-stage melanoma.
    Melanoma Res. 2018 Mar 8. doi: 10.1097/CMR.0000000000000436.
    PubMed     Abstract available


    February 2018
  233. MACHIRAJU D, Moll I, Gebhardt C, Sucker A, et al
    STAT5 expression correlates with recurrence and survival in melanoma patients treated with interferon-alpha.
    Melanoma Res. 2018 Feb 26. doi: 10.1097/CMR.0000000000000435.
    PubMed     Abstract available


  234. DIMITRIOU F, Frauchiger AL, Urosevic-Maiwald M, Naegeli MC, et al
    Sarcoid-like reactions in patients receiving modern melanoma treatment.
    Melanoma Res. 2018 Feb 26. doi: 10.1097/CMR.0000000000000437.
    PubMed     Abstract available


  235. GONZALEZ-CAO M, Mayo de Las Casas C, Jordana Ariza N, Manzano JL, et al
    Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapy.
    Melanoma Res. 2018 Feb 23. doi: 10.1097/CMR.0000000000000432.
    PubMed     Abstract available


  236. TESTORI AA, Suciu S, van Akkooi ACJ, Suppa M, et al
    Lymph node ratio as a prognostic factor in melanoma: results from European Organization for Research and Treatment of Cancer 18871, 18952, and 18991 studies.
    Melanoma Res. 2018 Feb 9. doi: 10.1097/CMR.0000000000000433.
    PubMed     Abstract available


  237. GANZETTI G, Sartini D, Campanati A, Rubini C, et al
    Nicotinamide N-methyltransferase: potential involvement in cutaneous malignant melanoma.
    Melanoma Res. 2018 Feb 7. doi: 10.1097/CMR.0000000000000430.
    PubMed     Abstract available


  238. YANAGITA M, Luke JJ, Hodi FS, Janne PA, et al
    Isolation and characterization of circulating melanoma cells by size filtration and fluorescent in-situ hybridization.
    Melanoma Res. 2018 Feb 5. doi: 10.1097/CMR.0000000000000431.
    PubMed     Abstract available


  239. KOTHAPALLI A, Khattak MA
    Safety and efficacy of anti-PD-1 therapy for metastatic melanoma and non-small-cell lung cancer in patients with viral hepatitis: a case series.
    Melanoma Res. 2018 Feb 5. doi: 10.1097/CMR.0000000000000434.
    PubMed     Abstract available


  240. EISENSTEIN A, Panova IP, Chung HJ, Goldberg LJ, et al
    Quantitative assessment of neuropilin-2 as a simple and sensitive diagnostic assay for spitzoid melanocytic lesions.
    Melanoma Res. 2018;28:71-75.
    PubMed     Abstract available


  241. ISAKOVIC AM, Petricevic SM, Ristic SM, Popadic DM, et al
    In vitro and in vivo antimelanoma effect of ethyl ester cyclohexyl analog of ethylenediamine dipropanoic acid.
    Melanoma Res. 2018;28:8-20.
    PubMed     Abstract available


    January 2018
  242. GEUKES FOPPEN MH, Boogerd W, Blank CU, van Thienen JV, et al
    Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma.
    Melanoma Res. 2018 Jan 19. doi: 10.1097/CMR.0000000000000429.
    PubMed     Abstract available


  243. NARDIN C, Mateus C, Texier M, Lanoy E, et al
    Tolerance and outcomes of stereotactic radiosurgery combined with anti-programmed cell death-1 (pembrolizumab) for melanoma brain metastases.
    Melanoma Res. 2018 Jan 19. doi: 10.1097/CMR.0000000000000413.
    PubMed     Abstract available


  244. ROSE AM, Radia UK, Luo R, Kalirai H, et al
    Multiple primary malignancies and prolonged survival in a patient with widespread metastatic cutaneous melanoma.
    Melanoma Res. 2018 Jan 17. doi: 10.1097/CMR.0000000000000426.
    PubMed    


  245. ZHU W, Li S, Zou B, Liu H, et al
    Expressions and clinical significance of HER4 and CD44 in sinonasal mucosal malignant melanoma.
    Melanoma Res. 2018 Jan 5. doi: 10.1097/CMR.0000000000000428.
    PubMed     Abstract available


  246. DANISH H, Ferris MJ, Balagamwala E, Switchenko JM, et al
    Comparative outcomes and toxicities for ruthenium-106 versus palladium-103 in the treatment of choroidal melanoma.
    Melanoma Res. 2018 Jan 3. doi: 10.1097/CMR.0000000000000420.
    PubMed     Abstract available


    December 2017
  247. DEL CARPIO HUERTA LP, Mas Castells M, Anguera Palacios G, Sullivan I, et al
    A novel KRAS mutation in metastasic conjunctival melanoma: a case report and literature review.
    Melanoma Res. 2017 Dec 20. doi: 10.1097/CMR.0000000000000423.
    PubMed     Abstract available


  248. WEITMAN ES, Perez M, Thompson JF, Andtbacka RHI, et al
    Quality of life patient-reported outcomes for locally advanced cutaneous melanoma.
    Melanoma Res. 2017 Dec 19. doi: 10.1097/CMR.0000000000000425.
    PubMed     Abstract available


  249. GALLO S, Coha V, Caravelli D, Becco P, et al
    BRAF-inhibitors can exert control of disease in BRAF T599I mutated melanoma: a case report.
    Melanoma Res. 2017 Dec 11. doi: 10.1097/CMR.0000000000000417.
    PubMed     Abstract available


  250. BISSCHOP C, Ter Elst A, Bosman LJ, Platteel I, et al
    Rapid BRAF mutation tests in patients with advanced melanoma: comparison of immunohistochemistry, Droplet Digital PCR, and the Idylla Mutation Platform.
    Melanoma Res. 2017 Dec 11. doi: 10.1097/CMR.0000000000000421.
    PubMed     Abstract available


  251. SEREMET T, Planken S, Schreuer M, Jansen Y, et al
    Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from anti-PD1 antibody therapy.
    Melanoma Res. 2017 Dec 8. doi: 10.1097/CMR.0000000000000415.
    PubMed     Abstract available


  252. LOYSON T, Werbrouck E, Punie K, Bonne L, et al
    Hemorrhage of liver and bone metastases as a result of rapid response to dual BRAF/MEK inhibition in metastatic melanoma: a case report.
    Melanoma Res. 2017 Dec 5. doi: 10.1097/CMR.0000000000000419.
    PubMed     Abstract available


  253. MENZIES S, Barry R, Ormond P
    Multiple primary melanoma: a single centre retrospective review.
    Melanoma Res. 2017;27:638-640.
    PubMed     Abstract available


  254. SCHINZARI G, Rossi E, Cassano A, Dadduzio V, et al
    Cisplatin, dacarbazine and vinblastine as first line chemotherapy for liver metastatic uveal melanoma in the era of immunotherapy: a single institution phase II study.
    Melanoma Res. 2017;27:591-595.
    PubMed     Abstract available


  255. HALLMEYER S, Gonzalez R, Lawson DH, Cranmer LD, et al
    Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E.
    Melanoma Res. 2017;27:585-590.
    PubMed     Abstract available


  256. ROBINSON JP, Rebecca VW, Kircher DA, Silvis MR, et al
    Resistance mechanisms to genetic suppression of mutant NRAS in melanoma.
    Melanoma Res. 2017;27:545-557.
    PubMed     Abstract available


  257. VAN DER WEYDEN L, Arends MJ, Brenn T, Tuting T, et al
    Widespread spontaneous hyperproliferation, melanosis and melanoma in Hgf-Cdk4R24C mice.
    Melanoma Res. 2017 Dec 1. doi: 10.1097/CMR.0000000000000414.
    PubMed    


    November 2017
  258. BRANCA M, Orso S, Molinari RC, Xu H, et al
    Is nonmetastatic cutaneous melanoma predictable through genomic biomarkers?
    Melanoma Res. 2017 Nov 29. doi: 10.1097/CMR.0000000000000412.
    PubMed     Abstract available


  259. CHESNEY J, Awasthi S, Curti B, Hutchins L, et al
    Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB-IVM1c melanoma.
    Melanoma Res. 2017 Nov 22. doi: 10.1097/CMR.0000000000000399.
    PubMed     Abstract available


  260. HADDEN NJ, McIntosh JRD, Jay S, Whittaker PJ, et al
    Prognostic factors in patients with metastatic spinal cord compression secondary to melanoma: a systematic review.
    Melanoma Res. 2017 Nov 14. doi: 10.1097/CMR.0000000000000411.
    PubMed     Abstract available


  261. KUO JC, Lilly LB, Hogg D
    Immune checkpoint inhibitor therapy in a liver transplant recipient with a rare subtype of melanoma: a case report and literature review.
    Melanoma Res. 2017 Nov 14. doi: 10.1097/CMR.0000000000000410.
    PubMed     Abstract available


  262. BRZOZOWSKA M, Wierzba W, Sliwczynski A, Swierkowski M, et al
    Analysis of survival of patients treated with vemurafenib, ipilimumab and dabrafenib for advanced skin melanoma in daily clinical practice (Real-World Data): retrospective analysis of patients treated under drug/reimbursement programmes in Poland in 2
    Melanoma Res. 2017 Nov 8. doi: 10.1097/CMR.0000000000000408.
    PubMed     Abstract available


    October 2017
  263. PACHMANN K, Willecke-Hochmuth R, Schneider K, Kaatz M, et al
    Circulating epithelial tumor cells as a prognostic tool for malignant melanoma.
    Melanoma Res. 2017 Oct 25. doi: 10.1097/CMR.0000000000000407.
    PubMed     Abstract available


  264. TANG Y, Xie C, Zhang Y, Qin Y, et al
    Overexpression of mRNA-decapping enzyme 1a predicts disease-specific survival in malignant melanoma.
    Melanoma Res. 2017 Oct 25. doi: 10.1097/CMR.0000000000000406.
    PubMed     Abstract available


  265. UPRETY D, Bista A, Chennamadhavuni A, Niroula A, et al
    Survival trends among patients with metastatic melanoma in the pretargeted and the post-targeted era: a US population-based study.
    Melanoma Res. 2017 Oct 11. doi: 10.1097/CMR.0000000000000394.
    PubMed     Abstract available


  266. FAILING JJ, Yan Y, Porrata LF, Markovic SN, et al
    Lymphocyte-to-monocyte ratio is associated with survival in pembrolizumab-treated metastatic melanoma patients.
    Melanoma Res. 2017 Oct 9. doi: 10.1097/CMR.0000000000000404.
    PubMed     Abstract available


  267. SHEN X, Fan Y, Cao S
    A review of primary malignant melanoma arising in an ovarian cystic teratoma.
    Melanoma Res. 2017 Oct 9. doi: 10.1097/CMR.0000000000000402.
    PubMed     Abstract available


  268. ALESSI C, Scapulatempo Neto C, Viana CR, Vazquez VL, et al
    PD-1/PD-L1 and VEGF-A/VEGF-C expression in lymph node microenvironment and association with melanoma metastasis and survival.
    Melanoma Res. 2017 Oct 3. doi: 10.1097/CMR.0000000000000396.
    PubMed     Abstract available


  269. TSIOGKA A, Jansky GL, Bauer JW, Koelblinger P, et al
    Fulminant type 1 diabetes after adjuvant ipilimumab therapy in cutaneous melanoma.
    Melanoma Res. 2017;27:524-525.
    PubMed    


  270. ABOUDARAM A, Modesto A, Chaltiel L, Gomez-Roca C, et al
    Concurrent radiotherapy for patients with metastatic melanoma and receiving anti-programmed-death 1 therapy: a safe and effective combination.
    Melanoma Res. 2017;27:485-491.
    PubMed     Abstract available


    September 2017
  271. MARTINEZ-GARCIA MA, Riveiro-Falkenbach E, Rodriguez-Peralto JL, Nagore E, et al
    A prospective multicenter cohort study of cutaneous melanoma: clinical staging and potential associations with HIF-1alpha and VEGF expressions.
    Melanoma Res. 2017 Sep 6. doi: 10.1097/CMR.0000000000000393.
    PubMed     Abstract available


  272. DE SOUZA NETO FP, Bernardes SS, Marinello PC, Melo GP, et al
    Metformin: oxidative and proliferative parameters in-vitro and in-vivo models of murine melanoma.
    Melanoma Res. 2017 Sep 4. doi: 10.1097/CMR.0000000000000391.
    PubMed     Abstract available


  273. YUKI A, Takenouchi T, Takatsuka S, Ishiguro T, et al
    A case of pure red cell aplasia during nivolumab therapy for cardiac metastatic melanoma.
    Melanoma Res. 2017 Sep 1. doi: 10.1097/CMR.0000000000000392.
    PubMed     Abstract available


  274. TAHA T, Tzuk-Shina T, Forschner I, Bar-Sela G, et al
    Acute motor and sensory axonal neuropathy related to treatment with MEK inhibitors in a patient with advanced melanoma.
    Melanoma Res. 2017 Sep 1. doi: 10.1097/CMR.0000000000000390.
    PubMed     Abstract available


    August 2017
  275. LI Y, Umbach DM, Li L
    Putative genomic characteristics of BRAF V600K versus V600E cutaneous melanoma.
    Melanoma Res. 2017 Aug 28. doi: 10.1097/CMR.0000000000000388.
    PubMed     Abstract available


  276. TARHINI AA, Floros T, Lin HM, Lin Y, et al
    A unique gene expression signature is significantly differentially expressed in tumor-positive or tumor-negative sentinel lymph nodes in patients with melanoma.
    Melanoma Res. 2017 Aug 18. doi: 10.1097/CMR.0000000000000383.
    PubMed     Abstract available


  277. GLITZA IC, Guha-Thakurta N, D'Souza NM, Amaria RN, et al
    Bevacizumab as an effective treatment for radiation necrosis after radiotherapy for melanoma brain metastases.
    Melanoma Res. 2017 Aug 16. doi: 10.1097/CMR.0000000000000389.
    PubMed     Abstract available


  278. PURI A, Homsi J
    The safety of pembrolizumab in metastatic melanoma and rheumatoid arthritis.
    Melanoma Res. 2017 Aug 16. doi: 10.1097/CMR.0000000000000387.
    PubMed     Abstract available


  279. BARBARIC J, Laversanne M, Znaor A
    Malignant melanoma incidence trends in a Mediterranean population following socioeconomic transition and war: results of age-period-cohort analysis in Croatia, 1989-2013.
    Melanoma Res. 2017 Aug 10. doi: 10.1097/CMR.0000000000000385.
    PubMed     Abstract available


  280. GARDNER LJ, Ward M, Andtbacka RHI, Boucher KM, et al
    Risk factors for development of melanoma brain metastasis and disease progression: a single-center retrospective analysis.
    Melanoma Res. 2017 Aug 10. doi: 10.1097/CMR.0000000000000382.
    PubMed     Abstract available


  281. ROGIERS A, Borght SV, Tuand K, Wolter P, et al
    Response to targeted therapy in two patients with metastatic melanoma carrying rare BRAF exon 15 mutations: A598_T599insV and V600_K601delinsE.
    Melanoma Res. 2017 Aug 10. doi: 10.1097/CMR.0000000000000376.
    PubMed     Abstract available


  282. GOGAS HJ, Karalexi MA, Dessypris N, Antoniadis AG, et al
    The role of depression and personality traits in patients with melanoma: a South-European study.
    Melanoma Res. 2017 Aug 10. doi: 10.1097/CMR.0000000000000380.
    PubMed     Abstract available


  283. GLADFELTER P, Darwish NHE, Mousa SA
    Current status and future direction in the management of malignant melanoma.
    Melanoma Res. 2017 Aug 10. doi: 10.1097/CMR.0000000000000379.
    PubMed     Abstract available


  284. GRANGE F, Mohr P, Harries M, Ehness R, et al
    Economic burden of advanced melanoma in France, Germany and the UK: a retrospective observational study (Melanoma Burden-of-Illness Study).
    Melanoma Res. 2017 Aug 10. doi: 10.1097/CMR.0000000000000372.
    PubMed     Abstract available


  285. STOWMAN AM, Hickman AW, Gru AA, Slingluff CL Jr, et al
    Histopathologic review of negative sentinel lymph node biopsies in thin melanomas: an argument for the routine use of immunohistochemistry.
    Melanoma Res. 2017;27:369-376.
    PubMed     Abstract available


  286. DE ROSA F, Ridolfi L, Fiammenghi L, Petrini M, et al
    Dendritic cell vaccination for metastatic melanoma: a 14-year monoinstitutional experience.
    Melanoma Res. 2017;27:351-357.
    PubMed     Abstract available


  287. SANGALLI A, Orlandi E, Poli A, Maurichi A, et al
    Sex-specific effect of RNASEL rs486907 and miR-146a rs2910164 polymorphisms' interaction as a susceptibility factor for melanoma skin cancer.
    Melanoma Res. 2017;27:309-314.
    PubMed     Abstract available


    July 2017
  288. SOSSAU D, Kofler L, Eigentler T
    Type 1 diabetes mellitus caused by treatment with low-dose interferon-alpha in a melanoma patient.
    Melanoma Res. 2017 Jul 19. doi: 10.1097/CMR.0000000000000381.
    PubMed     Abstract available


  289. BORGHI A, Corazza M, Virgili A, Lambertini AG, et al
    Impact of socioeconomic status and district of residence on cutaneous malignant melanoma prognosis: a survival study on incident cases between 1991 and 2011 in the province of Ferrara, northern Italy.
    Melanoma Res. 2017 Jul 18. doi: 10.1097/CMR.0000000000000378.
    PubMed     Abstract available


  290. GRATZ V, Luttmann N, Haase O, Langan EA, et al
    Meningeal melanomatosis following discontinuation of dabrafenib: implications for the maintenance of long-term complete remission.
    Melanoma Res. 2017 Jul 18. doi: 10.1097/CMR.0000000000000373.
    PubMed     Abstract available


  291. GAUCI ML, Laly P, Sarah LL, Behin A, et al
    Focal necrotizing myopathy with 'dropped-head syndrome' induced by cobimetinib in metastatic melanoma.
    Melanoma Res. 2017 Jul 7. doi: 10.1097/CMR.0000000000000377.
    PubMed     Abstract available


    June 2017
  292. WANDLER A, Riber-Hansen R, Hager H, Hamilton-Dutoit SJ, et al
    Quantification of microRNA-21 and microRNA-125b in melanoma tissue.
    Melanoma Res. 2017 Jun 13. doi: 10.1097/CMR.0000000000000374.
    PubMed     Abstract available


  293. TOMIZUKA T, Namikawa K, Higashi T
    Characteristics of melanoma in Japan: a nationwide registry analysis 2011-2013.
    Melanoma Res. 2017 Jun 12. doi: 10.1097/CMR.0000000000000375.
    PubMed     Abstract available


  294. SOARES CD, Borges CF, Sena-Filho M, Almeida OP, et al
    Prognostic significance of cyclooxygenase 2 and phosphorylated Akt1 overexpression in primary nonmetastatic and metastatic cutaneous melanomas.
    Melanoma Res. 2017 Jun 9. doi: 10.1097/CMR.0000000000000368.
    PubMed     Abstract available


  295. DAVICK JJ, Wick MR, Gru AA
    Development of a biclonal cutaneous T-cell lymphoproliferative process during treatment with immune checkpoint inhibitors for metastatic melanoma.
    Melanoma Res. 2017 Jun 1. doi: 10.1097/CMR.0000000000000371.
    PubMed     Abstract available


  296. GIUDICE G, Robusto F, Vestita M, Annoscia P, et al
    Single-stage excision and sentinel lymph node biopsy in cutaneous melanoma in selected patients: a retrospective case-control study.
    Melanoma Res. 2017 Jun 1. doi: 10.1097/CMR.0000000000000370.
    PubMed     Abstract available


  297. WANG Y, Wen XZ, Ba HJ, Li DD, et al
    A prognostic model for resectable acral melanoma patients on the basis of preoperative inflammatory markers.
    Melanoma Res. 2017 Jun 1. doi: 10.1097/CMR.0000000000000365.
    PubMed     Abstract available


  298. MIRZA S, Hill E, Ludlow SP, Nanjappa S, et al
    Checkpoint inhibitor-associated drug reaction with eosinophilia and systemic symptom syndrome.
    Melanoma Res. 2017;27:271-273.
    PubMed     Abstract available


  299. HAUEIS SA, Kranzlin P, Mangana J, Cheng PF, et al
    Does the distribution pattern of brain metastases during BRAF inhibitor therapy reflect phenotype switching?
    Melanoma Res. 2017;27:231-237.
    PubMed     Abstract available


    May 2017
  300. FURDOVA A, Sramka M, Chorvath M, Kralik G, et al
    Clinical experience of stereotactic radiosurgery at a linear accelerator for intraocular melanoma.
    Melanoma Res. 2017 May 17. doi: 10.1097/CMR.0000000000000364.
    PubMed     Abstract available


  301. MANGANA J, Cheng PF, Kaufmann C, Amann VC, et al
    Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland.
    Melanoma Res. 2017 May 15. doi: 10.1097/CMR.0000000000000359.
    PubMed     Abstract available


  302. GUADAGNI S, Fiorentini G, Clementi M, Palumbo G, et al
    MGMT methylation correlates with melphalan pelvic perfusion survival in stage III melanoma patients: a pilot study.
    Melanoma Res. 2017 May 10. doi: 10.1097/CMR.0000000000000367.
    PubMed     Abstract available


  303. LAKHTER AJ, Naidu SR
    Cyclic AMP-Epac signaling pathway contributes to repression of PUMA transcription in melanoma cells.
    Melanoma Res. 2017 May 4. doi: 10.1097/CMR.0000000000000363.
    PubMed     Abstract available


  304. HOLTKAMP LHJ, Read RL, Emmett L, Thompson JF, et al
    Futility of imaging to stage melanoma patients with a positive sentinel lymph node.
    Melanoma Res. 2017 May 4. doi: 10.1097/CMR.0000000000000362.
    PubMed     Abstract available


  305. STABLER S, Becquart C, Dumezy F, Terriou L, et al
    Hemophagocytic lymphohistiocytosis in patients with metastatic malignant melanoma.
    Melanoma Res. 2017 May 3. doi: 10.1097/CMR.0000000000000354.
    PubMed     Abstract available


    April 2017
  306. MENDT M, Cardier JE
    Activation of the CXCR4 chemokine receptor enhances biological functions associated with B16 melanoma liver metastasis.
    Melanoma Res. 2017 Apr 25. doi: 10.1097/CMR.0000000000000346.
    PubMed     Abstract available


  307. KYRGIDIS A, Lallas A, Moscarella E, Longo C, et al
    Does pregnancy influence melanoma prognosis? A meta-analysis.
    Melanoma Res. 2017 Apr 20. doi: 10.1097/CMR.0000000000000334.
    PubMed     Abstract available


  308. DIAMANTOPOULOS PT, Gaggadi M, Kassi E, Benopoulou O, et al
    Late-onset nivolumab-mediated pneumonitis in a patient with melanoma and multiple immune-related adverse events.
    Melanoma Res. 2017 Apr 17. doi: 10.1097/CMR.0000000000000355.
    PubMed     Abstract available


  309. PISCIOLI F, Pusiol T, Roncati L
    Critical points of T1 stage in primary melanoma.
    Melanoma Res. 2017 Apr 13. doi: 10.1097/CMR.0000000000000357.
    PubMed    


  310. MURER C, Kranzlin-Stieger P, French LE, Dummer R, et al
    Successful treatment with imatinib after nilotinib and ipilimumab in a c-kit-mutated advanced melanoma patient: a case report.
    Melanoma Res. 2017 Apr 13. doi: 10.1097/CMR.0000000000000358.
    PubMed     Abstract available


  311. TARHINI AA, Moschos SJ, Lin Y, Lin HM, et al
    Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-alpha2b in patients with metastatic melanoma.
    Melanoma Res. 2017 Apr 7. doi: 10.1097/CMR.0000000000000353.
    PubMed     Abstract available


  312. THOMSON CH, Cassell O, Peach H, Holloway S, et al
    Neuropathic pain and quality of life after wide local excision and sentinel lymph node biopsy for melanoma: a multicentre study.
    Melanoma Res. 2017;27:121-125.
    PubMed     Abstract available


  313. ROGIERS A, Wolter P, Bechter O
    Dabrafenib plus trametinib rechallenge in four melanoma patients who previously progressed on this combination.
    Melanoma Res. 2017;27:164-167.
    PubMed     Abstract available


  314. BLACKMON JT, Dhawan R, Terry NL, Conry RM, et al
    Response of BRAF inhibitor-associated squamous cell lung carcinoma to drug withdrawal.
    Melanoma Res. 2017;27:159-163.
    PubMed     Abstract available


  315. AMODE R, Baroudjian B, Kowal A, Jebali M, et al
    Anti-programmed cell death protein 1 tolerance and efficacy after ipilimumab immunotherapy: observational study of 39 patients.
    Melanoma Res. 2017;27:110-115.
    PubMed     Abstract available


    March 2017
  316. DE GIORGI V, Grazzini M, Benemei S, Marchionni N, et al
    beta-Blocker use and reduced disease progression in patients with thick melanoma: 8 years of follow-up.
    Melanoma Res. 2017 Mar 24. doi: 10.1097/CMR.0000000000000317.
    PubMed     Abstract available


  317. HINTZSCHE JD, Gorden NT, Amato CM, Kim J, et al
    Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma.
    Melanoma Res. 2017 Mar 14. doi: 10.1097/CMR.0000000000000345.
    PubMed     Abstract available


  318. LEON-FERRE RA, Kottschade LA, Block MS, McWilliams RR, et al
    Association between the use of surveillance PET/CT and the detection of potentially salvageable occult recurrences among patients with resected high-risk melanoma.
    Melanoma Res. 2017 Mar 14. doi: 10.1097/CMR.0000000000000344.
    PubMed     Abstract available


  319. CARRERA C, Gual A, Diaz A, Puig-Butille JA, et al
    Prognostic role of the histological subtype of melanoma on the hands and feet in Caucasians.
    Melanoma Res. 2017 Mar 14. doi: 10.1097/CMR.0000000000000340.
    PubMed     Abstract available


  320. FALLENI M, Savi F, Tosi D, Agape E, et al
    M1 and M2 macrophages' clinicopathological significance in cutaneous melanoma.
    Melanoma Res. 2017 Mar 7. doi: 10.1097/CMR.0000000000000352.
    PubMed     Abstract available


  321. FUKUDA K, Funakoshi T, Sakurai T, Nakamura Y, et al
    Peptide-pulsed dendritic cell vaccine in combination with carboplatin and paclitaxel chemotherapy for stage IV melanoma.
    Melanoma Res. 2017 Mar 3. doi: 10.1097/CMR.0000000000000342.
    PubMed     Abstract available


  322. BLASIG H, Bender C, Hassel JC, Eigentler TK, et al
    Reinduction of PD1-inhibitor therapy: first experience in eight patients with metastatic melanoma.
    Melanoma Res. 2017 Mar 2. doi: 10.1097/CMR.0000000000000341.
    PubMed     Abstract available


  323. DE GIORGI V, Gori A, Savarese I, D'Errico A, et al
    Clinical and dermoscopic features of truly amelanotic plantar melanoma.
    Melanoma Res. 2017 Mar 1. doi: 10.1097/CMR.0000000000000337.
    PubMed     Abstract available


  324. LOQUAI C, Schmidtmann I, Garzarolli M, Kaatz M, et al
    Interactions from complementary and alternative medicine in patients with melanoma.
    Melanoma Res. 2017 Mar 1. doi: 10.1097/CMR.0000000000000339.
    PubMed     Abstract available


    February 2017
  325. DESVIGNES C, Abirached H, Templier C, Drumez E, et al
    BRAF inhibitor discontinuation and rechallenge in advanced melanoma patients with a complete initial treatment response.
    Melanoma Res. 2017 Feb 24. doi: 10.1097/CMR.0000000000000350.
    PubMed     Abstract available


  326. TAS F, Erturk K
    Scalp melanoma is associated with high mitotic rate and is a poor prognostic factor for recurrence and outcome.
    Melanoma Res. 2017 Feb 23. doi: 10.1097/CMR.0000000000000351.
    PubMed     Abstract available


  327. VIZKELETI L, Kiss T, Koroknai V, Ecsedi S, et al
    Altered integrin expression patterns shown by microarray in human cutaneous melanoma.
    Melanoma Res. 2017 Feb 23. doi: 10.1097/CMR.0000000000000322.
    PubMed     Abstract available


  328. ITCHINS M, Ascierto PA, Menzies AM, Oatley M, et al
    A multireferral centre retrospective cohort analysis on the experience in treatment of metastatic uveal melanoma and utilization of sequential liver-directed treatment and immunotherapy.
    Melanoma Res. 2017 Feb 22. doi: 10.1097/CMR.0000000000000343.
    PubMed     Abstract available


  329. MADU MF, Timmerman P, Wouters MW, van der Hiel B, et al
    PET/CT surveillance detects asymptomatic recurrences in stage IIIB and IIIC melanoma patients: a prospective cohort study.
    Melanoma Res. 2017 Feb 20. doi: 10.1097/CMR.0000000000000347.
    PubMed     Abstract available


  330. LI FJ, Li LM, Zhang RH, Xu C, et al
    The role of 5-hydroxymethylcytosine in melanoma.
    Melanoma Res. 2017 Feb 20. doi: 10.1097/CMR.0000000000000349.
    PubMed     Abstract available


  331. TESIO V, Ribero S, Castelli L, Bassino S, et al
    Psychological characteristics of early-stage melanoma patients: a cross-sectional study on 204 patients.
    Melanoma Res. 2017 Feb 15. doi: 10.1097/CMR.0000000000000348.
    PubMed     Abstract available


  332. RIBERO S, Longo C, Specchio F, Piana S, et al
    Lymph nodes' capsular naevi are associated with high naevus count in melanoma patients: a case-control study.
    Melanoma Res. 2017 Feb 1. doi: 10.1097/CMR.0000000000000328.
    PubMed     Abstract available


    January 2017
  333. PELLEGRINI C, Maturo MG, Martorelli C, Suppa M, et al
    Characterization of melanoma susceptibility genes in high-risk patients from Central Italy.
    Melanoma Res. 2017 Jan 31. doi: 10.1097/CMR.0000000000000323.
    PubMed     Abstract available


  334. LINO-SILVA LS, Salcedo-Hernandez RA, Garcia-Perez L, Meneses-Garcia A, et al
    Basal neutrophil-to-lymphocyte ratio is associated with overall survival in melanoma.
    Melanoma Res. 2017 Jan 25. doi: 10.1097/CMR.0000000000000333.
    PubMed     Abstract available


  335. GRAY A, Grushchak S, Mudaliar K, Kliethermes S, et al
    The microenvironment in primary cutaneous melanoma with associated spontaneous tumor regression: evaluation for T-regulatory cells and the presence of an immunosuppressive microenvironment.
    Melanoma Res. 2017 Jan 25. doi: 10.1097/CMR.0000000000000331.
    PubMed     Abstract available


  336. OBEID JM, Hu Y, Erdag G, Leick KM, et al
    The heterogeneity of tumor-infiltrating CD8+ T cells in metastatic melanoma distorts their quantification: how to manage heterogeneity?
    Melanoma Res. 2017 Jan 21. doi: 10.1097/CMR.0000000000000330.
    PubMed     Abstract available


  337. OBA J, Esmaeli B, Ellerhorst JA, Lyons GR, et al
    Trends in hepatocyte growth factor, insulin-like growth factor 1, thyroid-stimulating hormone, and leptin expression levels in uveal melanoma patient serum and tumor tissues: correlation to disease progression.
    Melanoma Res. 2017 Jan 21. doi: 10.1097/CMR.0000000000000329.
    PubMed     Abstract available


  338. LADWA R, Atkinson V
    The cessation of anti-PD-1 antibodies of complete responders in metastatic melanoma.
    Melanoma Res. 2017 Jan 17. doi: 10.1097/CMR.0000000000000336.
    PubMed     Abstract available


  339. TAS F, Erturk K
    Recurrence behavior in early-stage cutaneous melanoma: pattern, timing, survival, and influencing factors.
    Melanoma Res. 2017 Jan 17. doi: 10.1097/CMR.0000000000000332.
    PubMed     Abstract available


  340. DE HAAN J, Lok CA, de Groot CJ, Crijns MB, et al
    Melanoma during pregnancy: a report of 60 pregnancies complicated by melanoma.
    Melanoma Res. 2017 Jan 17. doi: 10.1097/CMR.0000000000000327.
    PubMed     Abstract available


  341. LV C, Dai H, Sun M, Zhao H, et al
    Mesenchymal stem cells induce epithelial mesenchymal transition in melanoma by paracrine secretion of transforming growth factor-beta.
    Melanoma Res. 2017 Jan 5. doi: 10.1097/CMR.0000000000000325.
    PubMed     Abstract available


  342. BORRONI RG, Manganoni AM, Grassi S, Grasso M, et al
    Genetic counselling and high-penetrance susceptibility gene analysis reveal the novel CDKN2A p.D84V (c.251A>T) mutation in melanoma-prone families from Italy.
    Melanoma Res. 2017 Jan 4. doi: 10.1097/CMR.0000000000000324.
    PubMed     Abstract available


    December 2016
  343. LINO-SILVA LS, Castillo-Medina AL, Salcedo-Hernandez RA, Garcia-Perez L, et al
    Exhaustive pathologic work-up in sentinel lymph node biopsy for melanoma: is it necessary?
    Melanoma Res. 2016 Dec 27. doi: 10.1097/CMR.0000000000000319.
    PubMed     Abstract available


  344. MICEVIC G, Theodosakis N, Taube JM, Bosenberg MW, et al
    Attenuation of genome-wide 5-methylcytosine level is an epigenetic feature of cutaneous malignant melanomas.
    Melanoma Res. 2016 Dec 16. doi: 10.1097/CMR.0000000000000315.
    PubMed     Abstract available


  345. BEHLING J, Kaes J, Munzel T, Grabbe S, et al
    New-onset third-degree atrioventricular block because of autoimmune-induced myositis under treatment with anti-programmed cell death-1 (nivolumab) for metastatic melanoma.
    Melanoma Res. 2016.
    PubMed     Abstract available


  346. MININI R, Rohrmann S, Braun R, Korol D, et al
    Incidence trends and clinical-pathological characteristics of invasive cutaneous melanoma from 1980 to 2010 in the canton of Zurich, Switzerland.
    Melanoma Res. 2016.
    PubMed     Abstract available


  347. PISCIOLI F, Pusiol T, Roncati L
    Thin melanoma subtyping fits well with the American Joint Committee on Cancer staging system.
    Melanoma Res. 2016;26:636.
    PubMed    


  348. PISCIOLI F, Pusiol T, Roncati L
    Histopathological determination of thin melanomas at risk for metastasis.
    Melanoma Res. 2016;26:635.
    PubMed    


    November 2016
  349. LEONTOVICH AA, Dronca RS, Nevala WK, Thompson MA, et al
    Effect of the lymphocyte-to-monocyte ratio on the clinical outcome of chemotherapy administration in advanced melanoma patients.
    Melanoma Res. 2016.
    PubMed     Abstract available


    October 2016
  350. PAOLINO G, Panetta C, Cota C, Didona D, et al
    Vitamin D receptor immunohistochemistry variability in sun-exposed and non-sun-exposed melanomas.
    Melanoma Res. 2016.
    PubMed     Abstract available


  351. SHOUSHTARI AN, Bluth MJ, Goldman DA, Bitas C, et al
    Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanoma.
    Melanoma Res. 2016.
    PubMed     Abstract available


  352. NGUYEN BH, Kuo J, Budiman A, Christie H, et al
    Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients.
    Melanoma Res. 2016.
    PubMed     Abstract available


  353. VARTANIAN A, Baryshnikova M, Burova O, Afanasyeva D, et al
    Inhibitor of vasculogenic mimicry restores sensitivity of resistant melanoma cells to DNA-damaging agents.
    Melanoma Res. 2016.
    PubMed     Abstract available


  354. CHAKRAVARTI N, Ivan D, Trinh VA, Glitza IC, et al
    High cytotoxic T-lymphocyte-associated antigen 4 and phospho-Akt expression in tumor samples predicts poor clinical outcomes in ipilimumab-treated melanoma patients.
    Melanoma Res. 2016.
    PubMed     Abstract available


  355. LIM MS, Wang JH, Power DG, Redmond HP, et al
    Inflammatory regulation of stem-like cells in melanoma.
    Melanoma Res. 2016.
    PubMed     Abstract available


  356. ADAMS G, Foote M, Brown S, Burmeister B, et al
    Adjuvant external beam radiotherapy after therapeutic groin lymphadenectomy for patients with melanoma: a dosimetric comparison of three-dimensional conformal and intensity-modulated radiotherapy techniques.
    Melanoma Res. 2016.
    PubMed     Abstract available


  357. BOTTLAENDER L, Perier-Muzet M, Lapras V, Thomas L, et al
    Tumor-free osteosclerotic lesions in patients treated for metastatic melanoma using BRAF inhibitors.
    Melanoma Res. 2016.
    PubMed     Abstract available


  358. AMBER KT, Panganiban CM, Korta D, Feraudy S, et al
    A case report of bullous pemphigoid associated with a melanoma and review of the literature.
    Melanoma Res. 2016.
    PubMed     Abstract available


  359. MATHESON JA, Te Marvelde L, Mailer S, Speakman D, et al
    Prospective evaluation of prognostic indicators for early recurrence of cutaneous melanoma.
    Melanoma Res. 2016.
    PubMed     Abstract available


    September 2016
  360. KUBECEK O, Kopecky J
    Microsatellite instability in melanoma: a comprehensive review.
    Melanoma Res. 2016.
    PubMed     Abstract available


  361. MIRJACIC MARTINOVIC KM, Babovic NL, Dzodic RR, Jurisic VB, et al
    Beneficial in-vitro effects of interleukin-2, interleukin-12, and their combination on functional and receptor characteristics of natural killer cells in metastatic melanoma patients with normal serum lactate dehydrogenase levels.
    Melanoma Res. 2016.
    PubMed     Abstract available


    April 2016
  362. CHENG C, Yang HW, Shang JF, Li WW, et al
    Identification of a small molecule that downregulates MITF expression and mediates antimelanoma activity in vitro.
    Melanoma Res. 2016;26:117-24.
    PubMed     Abstract available


  363. WANG LE, Li C, Xiong P, Gershenwald JE, et al
    4-nitroquinoline-1-oxide-induced mutagen sensitivity and risk of cutaneous melanoma: a case-control analysis.
    Melanoma Res. 2016;26:181-7.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: